<SEC-DOCUMENT>0001641172-25-018256.txt : 20250708
<SEC-HEADER>0001641172-25-018256.hdr.sgml : 20250708
<ACCEPTANCE-DATETIME>20250708172911
ACCESSION NUMBER:		0001641172-25-018256
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		21
CONFORMED PERIOD OF REPORT:	20250708
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250708
DATE AS OF CHANGE:		20250708

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIXTE BIOTECHNOLOGY HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001335105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				202903526
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39717
		FILM NUMBER:		251111799

	BUSINESS ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733
		BUSINESS PHONE:		310 203 2902

	MAIL ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SRKP 7 INC
		DATE OF NAME CHANGE:	20050803
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:LIXT="http://lixte.com/20250708">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_LIXT_lixte.com_20250708 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20250708_20250708 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001335105 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-07-08" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-07-08" id="Fact000004" name="dei:EntityCentralIndexKey">0001335105</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lixt-20250708.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-07-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-08</xbrli:startDate>
        <xbrli:endDate>2025-07-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-082025-07-08_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-08</xbrli:startDate>
        <xbrli:endDate>2025-07-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-082025-07-08_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-08</xbrli:startDate>
        <xbrli:endDate>2025-07-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt">UNITED
STATES</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt">SECURITIES
AND EXCHANGE COMMISSION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt">FORM
<span id="xdx_90D_edei--DocumentType_c20250708__20250708_zvX0dOHApRR1"><ix:nonNumeric contextRef="AsOf2025-07-08" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
REPORT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURSUANT
TO SECTION 13 OR 15(d) OF THE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES
EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <span id="xdx_904_edei--DocumentPeriodEndDate_c20250708__20250708_za3qBITPQ751"><ix:nonNumeric contextRef="AsOf2025-07-08" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">July 8, 2025</ix:nonNumeric></span> (July 3, 2025)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_902_edei--EntityRegistrantName_c20250708__20250708_z5qsIUgPfi97"><ix:nonNumeric contextRef="AsOf2025-07-08" id="Fact000011" name="dei:EntityRegistrantName">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20250708__20250708_zMuq2r45vsB6" style="text-transform: uppercase"><ix:nonNumeric contextRef="AsOf2025-07-08" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">delaware</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntityFileNumber_c20250708__20250708_zniEvr5B58g1"><ix:nonNumeric contextRef="AsOf2025-07-08" id="Fact000013" name="dei:EntityFileNumber">001-39717</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20250708__20250708_zAlAi5bP4qy8"><ix:nonNumeric contextRef="AsOf2025-07-08" id="Fact000014" name="dei:EntityTaxIdentificationNumber">20-2903526</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityAddressAddressLine1_c20250708__20250708_zNCOqJl5NROk"><ix:nonNumeric contextRef="AsOf2025-07-08" id="Fact000015" name="dei:EntityAddressAddressLine1">680
East Colorado Boulevard</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressAddressLine2_c20250708__20250708_zjGIDuiMLUn5"><ix:nonNumeric contextRef="AsOf2025-07-08" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 180</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntityAddressCityOrTown_c20250708__20250708_zLV51uLqEDGd"><ix:nonNumeric contextRef="AsOf2025-07-08" id="Fact000017" name="dei:EntityAddressCityOrTown">Pasadena</ix:nonNumeric></span>,
<span id="xdx_908_edei--EntityAddressStateOrProvince_c20250708__20250708_zn9E1eKSh7K8"><ix:nonNumeric contextRef="AsOf2025-07-08" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_908_edei--EntityAddressPostalZipCode_c20250708__20250708_zsSFaRzYNyDh"><ix:nonNumeric contextRef="AsOf2025-07-08" id="Fact000019" name="dei:EntityAddressPostalZipCode">91101</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--CityAreaCode_c20250708__20250708_zA4kwuDBVfA9"><ix:nonNumeric contextRef="AsOf2025-07-08" id="Fact000020" name="dei:CityAreaCode">(631)</ix:nonNumeric></span>
<span id="xdx_901_edei--LocalPhoneNumber_c20250708__20250708_zPOyAOjqDCii"><ix:nonNumeric contextRef="AsOf2025-07-08" id="Fact000021" name="dei:LocalPhoneNumber">830-7092</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (See General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--WrittenCommunications_c20250708__20250708_zH5SyYBvCY8j"><ix:nonNumeric contextRef="AsOf2025-07-08" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
                                            communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--SolicitingMaterial_c20250708__20250708_zH3VdFhtYNjj"><ix:nonNumeric contextRef="AsOf2025-07-08" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
                                            material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--PreCommencementTenderOffer_c20250708__20250708_zeCaaPSKxgWj"><ix:nonNumeric contextRef="AsOf2025-07-08" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
                                            communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20250708__20250708_zjb7nl6ibUX8"><ix:nonNumeric contextRef="AsOf2025-07-08" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
                                            communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Each Class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20250708__20250708__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zTiOnxbqldz"><ix:nonNumeric contextRef="From2025-07-082025-07-08_custom_CommonStockParValue0.0001PerShareMember" id="Fact000026" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20250708__20250708__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zw0NzXIewHBd"><ix:nonNumeric contextRef="From2025-07-082025-07-08_custom_CommonStockParValue0.0001PerShareMember" id="Fact000027" name="dei:TradingSymbol">LIXT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--SecurityExchangeName_c20250708__20250708__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zKcTYTnbVH9h"><ix:nonNumeric contextRef="From2025-07-082025-07-08_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The
    NASDAQ Stock Market, LLC</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--Security12bTitle_c20250708__20250708__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_zFGcbXl36vf6"><ix:nonNumeric contextRef="From2025-07-082025-07-08_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" id="Fact000029" name="dei:Security12bTitle">Warrants
    to Purchase Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--TradingSymbol_c20250708__20250708__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_zOLRqY9zg5Fa"><ix:nonNumeric contextRef="From2025-07-082025-07-08_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" id="Fact000030" name="dei:TradingSymbol">LIXTW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--SecurityExchangeName_c20250708__20250708__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_zyqX7O6MzAGd"><ix:nonNumeric contextRef="From2025-07-082025-07-08_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">The
    NASDAQ Stock Market, LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_904_edei--EntityEmergingGrowthCompany_c20250708__20250708_zqZxir5GpYp8"><ix:nonNumeric contextRef="AsOf2025-07-08" format="ixt:booleanfalse" id="Fact000032" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 1.01</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry Into a Material Agreement.</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 3, 2025, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into a Securities Purchase
Agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers named therein (the &#8220;Purchasers&#8221;), pursuant to which
the Company agreed to issue and sell, in a registered direct offering (the &#8220;Offering&#8221;) 210,675 shares (the &#8220;Common
Shares&#8221;) of the Company&#8217;s Common Stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;) and Pre-Funded Warrants
(&#8220;Pre-Funded Warrants&#8221;) to purchase 763,351 shares of Common Stock at an offering price of $1.54 per share (or $1.53999 per
Pre-Funded Warrant).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering resulted in gross proceeds of approximately $1,500,000 before deducting placement agent&#8217;s fees and related offering expenses.
The Offering closed on July 8, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
representations, warranties and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to the
Purchase Agreement. In addition, such representations, warranties and covenants (i) are intended as a way of allocating the risk between
the parties to the Purchase Agreement and not as statements of fact, and (ii) may apply standards of materiality in a way that is different
from what may be viewed as material by stockholders of, or other investors in, the Company. Accordingly, the Purchase Agreement is included
with this filing only to provide investors with information regarding the terms of the transaction, and not to provide investors with
any other factual information regarding the Company. Moreover, information concerning the subject matter of the representations and warranties
may change after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to <span style="background-color: white">a Placement Agent Agreement dated as of July 3, 2025 (the &#8220;Placement Agent Agreement&#8221;),
the Company engaged Spartan Capital Securities, LLC (the &#8220;Placement Agent&#8221;) </span>to act as the Company&#8217;s exclusive
placement agent in connection with the Offering. The Company paid the Placement Agent a cash fee equal to 8.0% of the aggregate gross
proceeds raised in the Offering, and agreed to reimburse the Placement Agent $40,000 for its legal fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing summaries of the Purchase Agreement and Placement Agent Agreement do not purport to be complete and are subject to, and qualified
in their entirety by such documents attached as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K, and which are
incorporated herein in their entirety by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
Company is filing the opinion of its counsel, TroyGould PC, relating to the legality of the issuance and sale of the Common Shares and
Pre-Funded Warrants as Exhibit 5.1 hereto and incorporated by reference.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Report does not constitute an offer to sell any securities or a solicitation of an offer to buy any securities, nor shall there be any
sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 8.01.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Events.</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in Item 1.01 above is hereby incorporated by reference into this Item 8.01. In connection with the Offering, on July 8, 2025,
the Company issued a press release announcing the closing of the Offering. A copy of the press release is filed as Exhibit 99.1 hereto
and is incorporated by reference.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
There is filed as part of this report the exhibits listed on the accompanying Index to Exhibits, which exhibits are incorporated herein
by reference</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    July 8, 2025</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</span></span></p>

</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">(Registrant)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>By:</i></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Geordan Pursglove</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geordan
    Pursglove </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Chief
    Executive Officer </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Form of Pre-Funded Warrant</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Opinion of TroyGould PC</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Form of Securities Purchase Agreement</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-2.htm">Form of Placement Agent Agreement</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press Release dated July 8, 2025</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL Document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJydkE1OwzAQhU/QO4willFrR+JH2UFUKkSKorZq2Q7plFpNPNHYKe2RuCVOQsWGDViWLHvmfe+NoyiOZvxoKhJ4fVjksKK6qdATLGhHQrak0JE9PacQzgW9G+cFre+vF2HGQUNBczPWGN77zqNxtE1B3U7U3SS5BqVTpaGYR6OunrHdmS1Zb7ACtFsohBsx5FHOA2GFJ7Zcn3unNYkzbFPQYzWUPyFROoEXPuIHy8FBnmfRKO7XKJoJt03omp482U4J04rqYOcG9c/u05St81ynG5RuNrfiopVyj47CZDXbpefyUKCssWpJjZVSuiBZ7lFoTvUbSUBolSRa3X+nu5DAM1xYMMCgp8XQoMCxA8LVgIQmfKXroL9E+2+QP3t+AaYXnxo= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTERED
PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: [&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: July 3, 2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    Date: July 7, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK</B> (the &ldquo;<B><U>Warrant</U></B>&rdquo;) certifies that, for value received, [&#9679;]
or its assigns (the &ldquo;<B><U>Holder</U></B>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time until this Warrant is exercised in full (the &ldquo;<B><U>Termination Date</U></B>&rdquo;),
to subscribe for and purchase from Lixte Biotechnology Holdings, Inc., a Delaware corporation (the &ldquo;<B><U>Company</U></B>&rdquo;),
up to [&#9679;] shares (as subject to adjustment hereunder, the &ldquo;<B><U>Warrant Shares</U></B>&rdquo;) of Common Stock. Subject
to the provisions of Section &lrm;2.3, the purchase price of one (1) share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section &lrm;2.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Definitions</U></B>.
                                            In addition to the terms defined elsewhere in this Warrant or in the Securities Purchase
                                            Agreement dated July 3, 2025 by and among the Company and the investors (the &ldquo;<B><U>Purchasers</U></B>&rdquo;)
                                            referred to therein (the &ldquo;<B><U>Securities Purchase Agreement</U></B>&rdquo;), the
                                            following terms have the meanings indicated in this Section &lrm;1:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
&ldquo;<B><U>Affiliate</U></B>&rdquo; means any Person that, directly or indirectly through one or more intermediaries, controls or is
controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
&ldquo;<B><U>Bid Price</U></B>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a)
if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the
nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB Venture Market or OTCQX Best Market
is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB
or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported on the OTC Markets Group. (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common
Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then
outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3.
&ldquo;<B><U>Board of Directors</U></B>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4.
&ldquo;<B><U>Business Day</U></B>&rdquo; means a Calendar Day other than a Saturday, Sunday or any other Calendar Day which is a federal
legal holiday in the United States or any Calendar Day on which the commercial banks in the City of New York are required by law or other
governmental action to close, provided that the commercial banks in the City of New York shall not be deemed to be required to be closed
due to a &ldquo;stay at home,&rdquo; &ldquo;shelter in place,&rdquo; &ldquo;non-essential employee&rdquo; or similar orders or restrictions
or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer
systems (including for wire transfers) of commercial banks in the City of New York generally are open for use by customers on such Calendar
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5.
&ldquo;<B><U>Calendar Day</U></B>&rdquo; means each and every day of the week (Sunday, Monday, Tuesday, Wednesday, Thursday, Friday and
Saturday).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6.
&ldquo;<B><U>Commission</U></B>&rdquo; means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7.
&ldquo;<B><U>Common Stock</U></B>&rdquo; means the common stock of the Company, $0.0001 par value per share, and any other class of securities
into which such securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8.
&ldquo;<B><U>Common Stock Equivalents</U></B>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the
holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant
or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof
to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9.
&ldquo;<B><U>Exchange Act</U></B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10.
&ldquo;<B><U>Exempt Issuance</U></B>&rdquo; means (i) any conventional bank loans that are not convertible into, or exercisable or exchangeable
for, shares of Common Stock or Common Stock Equivalents and do not involve any issuance of any shares of Common Stock or Common Stock
Equivalents or other security of the Company in connection therewith; (ii) shares of Common Stock or options issued to employees, officers
or directors of the Company pursuant to the Company&rsquo;s equity incentive plans or pursuant to the compensation agreements previously
authorized by the Board of Directors; (iii) securities issued upon the exercise or exchange of or conversion of any Securities issued
hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on
the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number
of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection
with stock splits or combinations) or to extend the term of such securities; and (iv) securities issued pursuant to acquisitions or strategic
transactions (whether by merger, consolidation, purchase of equity, purchase of assets, reorganization or otherwise) approved by a majority
of the disinterested directors of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined
in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith
during the sixty (60) days following the Release Date, and provided that any such issuance shall only be to a Person (or to the equityholders
of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with
the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not
include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary
business is investing in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11.
&ldquo;<B><U>Person</U></B>&rdquo; means an individual or corporation, partnership, trust, incorporated or unincorporated association,
joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any
kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12.
&ldquo;<B><U>Registration Statement</U></B>&rdquo; means the Company&rsquo;s registration statement on Form S-3 (File No. 333-278874).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13.
&ldquo;<B><U>Release Date</U></B>&rdquo; means the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14.
&ldquo;<B><U>Securities Act</U></B>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15.
&ldquo;<B><U>Subsidiary</U></B>&rdquo; means any subsidiary of the Company and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16.
&ldquo;<B><U>Trading Day</U></B>&rdquo; means a Calendar Day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.17.
&ldquo;<B><U>Trading Market</U></B>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted
for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select
Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18.
&ldquo;<B><U>Transaction Documents</U></B>&rdquo; means the Securities Purchase Agreement dated July 3, 2025, these Warrants, such other
Warrants as contemplated in the Securities Purchase Agreement, the Registration Rights Agreement, the Placement Agent Agreement, the
Lock-Up Agreement and all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with
the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.19.
&ldquo;<B><U>Transfer Agent</U></B>&rdquo; means Computershare Trust Company, N.A., the current transfer agent of the Company, with a
mailing address of 150 Royall Street, Suite 101 Canton, MA 02021, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20.
&ldquo;<B><U>VWAP</U></B>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if
the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P.
(based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported
on the OTC Marekts Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent
bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.21.
&ldquo;<B><U>Warrants</U></B>&rdquo; means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the
Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exercise</U>.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.
<B><U>Exercise of Warrant</U></B>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise substantially in the form attached hereto as <U>Exhibit
&lrm;2.1</U> (the &ldquo;<B><U>Notice of Exercise</U></B>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii) the number
of Trading Days comprising the Standard Settlement Period (as defined in Section &lrm;2.7.1 herein) following the date of exercise as
aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise
by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section &lrm;2.3
below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of
the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
to the Company for cancellation within three (3) Trading Days after the date on which the final Notice of Exercise is delivered to the
Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder
shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable
number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased
and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day after receipt
of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions
of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.
<B><U>Exercise Price</U></B>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.00001 per Warrant
Share, subject to adjustment hereunder (such nominal exercise price, the &ldquo;<B><U>Exercise Price</U></B>&rdquo;), was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than such Exercise Price)
shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not be entitled to
the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever.
The remaining unpaid exercise price per Warrant Share is $0.00001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.
<B><U>Cashless Exercise</U></B>. This Warrant may also be exercised, in whole or in part, by means of a &ldquo;cashless exercise&rdquo;
in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by
(A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.36in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
                                            =</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable
                                            Notice of Exercise if such Notice of Exercise is (1) delivered pursuant to Section &lrm;2.1
                                            hereof on a Calendar Day that is not a Trading Day or (2) delivered pursuant to Section &lrm;2.1
                                            hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined
                                            in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading
                                            Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately
                                            preceding the date of the applicable Notice of Exercise or (z) the highest Bid Price of the
                                            Common Stock on the principal Trading Market as reported by Bloomberg L.P. within two (2)
                                            hours of the Holder&rsquo;s delivery of the Notice of Exercise pursuant to Section &lrm;2.1
                                            hereof if such Notice of Exercise is delivered during &ldquo;regular trading hours,&rdquo;
                                            or within two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading
                                            Day or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such
                                            Notice of Exercise is a Trading Day and such Notice of Exercise is delivered pursuant to
                                            Section &lrm;2.1 hereof two (2) or more hours following the close of &ldquo;regular trading
                                            hours&rdquo; on such Trading Day;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
                                            =</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
                                            =</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance
                                            with the terms of this Warrant if such exercise were by means of a cash exercise rather than
                                            a cashless exercise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.
<B><U>Holding Period for Cashless Exercise</U></B>. If Warrant Shares are issued in a cashless exercise, the parties acknowledge and
agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics
of the Warrants being exercised. Assuming (i) the Holder is not an Affiliate of the Company, and (ii) all of the applicable conditions
of Rule 144 promulgated under the Securities Act with respect to Holder and the Warrant Shares are met in the case of such a cashless
exercise, the Company agrees that the Company will cause the removal of the legend from such Warrant Shares (including by delivering
an opinion of TroyGould PC to the Company&rsquo;s transfer agent at its own expense to ensure the foregoing), and the Company agrees
that the Holder is under no obligation to sell the Warrant Shares issuable upon the exercise of the Warrant prior to removing the legend.
The Company agrees not to take any position contrary to this Section &lrm;2.6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.
<B><U>Mechanics of Exercise</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.1.
<B><U>Delivery of Warrant Shares upon Exercise</U></B>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<B><U>DWAC</U></B>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise and otherwise by physical delivery of a
certificate or by electronic delivery (at the election of the Holder), for the number of Warrant Shares to which the Holder is entitled
pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one
(1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard
Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<B><U>Warrant Share Delivery Date</U></B>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier
of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice
of Exercise. Notwithstanding anything herein to the contrary, upon delivery of the Notice of Exercise, the Holder shall immediately be
deemed for purposes of Regulation SHO under the Exchange Act to have become the holder of the Warrant Shares irrespective of the date
of delivery of the Warrant Shares. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice
of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty,
for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice
of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third (3rd) Trading Day after the Warrant Share Delivery
Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.
The Company agrees to maintain a Transfer Agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;<B><U>Standard Settlement Period</U></B>&rdquo; means the standard settlement period, expressed
in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date
of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior
to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the
Securities Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City
time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided
that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.2.
<B><U>Delivery of New Warrants Upon Exercise</U></B>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant
shall in all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.3.
<B><U>Rescission Rights</U></B>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section &lrm;2.7.1 by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.4.
<B><U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares upon Exercise</U></B>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section &lrm;2.7.1 above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is
required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases,
shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving
upon such exercise (a &ldquo;<B><U>Buy-In</U></B>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by
which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased
exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder
in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed,
and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such
exercise was not honored and return any amount received by the Company in respect of the Exercise Price for those Warrant Shares (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.5.
<B><U>No Fractional Shares or Scrip</U></B>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.6.
<B><U>Charges, Taxes and Expenses</U></B>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as <U>Exhibit &lrm;2.7.6</U> duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer
tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-Trading Day processing of any Notice of Exercise
and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for
same-Trading Day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.7.
<B><U>Closing of Books</U></B>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.
<B><U>Holder&rsquo;s Exercise Limitations</U></B>. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section &lrm;2 or otherwise, to the extent that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates,
and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<B><U>Attribution
Parties</U></B>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties
shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is
being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, unexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion
of the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any other Common Stock
Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the
Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section &lrm;2.8,
beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.
To the extent that the limitation contained in this Section &lrm;2.8 applies, the determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this
Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial
Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition,
a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder. For purposes of this Section &lrm;2.8, in determining the number of outstanding
shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company
or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates
or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<B><U>Beneficial
Ownership Limitation</U></B>&rdquo; shall be 4.99% of the number of shares of Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The provisions of this paragraph shall be construed
and implemented in a manner otherwise than in strict conformity with the terms of this Section &lrm;2.8 to correct this paragraph (or
any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make
changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Certain
                                            Adjustments</U>.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.
<B><U>Stock Dividends and Splits</U></B>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares
of Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of
which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of Shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section &lrm;3.1 shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.
<B><U>Subsequent Rights Offerings</U></B>. In addition to any adjustments pursuant to Section &lrm;3.1 above, if at any time the Company
grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to
all (or substantially all) of the record holders of any class of shares of Common Stock (the &ldquo;<B><U>Purchase Rights</U></B>&rdquo;),
then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the
Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant
(without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately
before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent
(or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to
such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.
<B><U>Pro Rata Distributions</U></B>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend
or other distribution of its assets (or rights to acquire its assets) to all (or substantially all) holders of shares of Common Stock,
by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property
or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
(a &ldquo;<B><U>Distribution</U></B>&rdquo;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall
be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for
such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined
for the participation in such Distribution (provided, however, that, to the extent that the Holder&rsquo;s right to participate in any
such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to
participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution
to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever,
as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has
not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance
for the benefit of the Holder until the Holder has exercised this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.
<B><U>Fundamental Transaction</U></B>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or
any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all
or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender
offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock
or 50% or more of the voting power of the common equity of the Company (each a &ldquo;<B><U>Fundamental Transaction</U></B>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section &lrm;2.8 on the exercise of this Warrant), the number of shares of Common Stock of the successor
or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<B><U>Alternate
Consideration</U></B>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock
for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section
&lrm;2.8 on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of
Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock
are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given
the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<B><U>Successor
Entity</U></B>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents
in accordance with the provisions of this Section &lrm;3.8 pursuant to written agreements in form and substance reasonably satisfactory
to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option
of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant that is exercisable for a corresponding number of shares of capital stock
of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise
price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares
of Common Stock prior to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital
stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation
of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any
such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Warrant (so that from
and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction
Documents referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor Entities,
jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right
and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company
prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity
or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled
to the benefits of the provisions of this Section &lrm;3.8 regardless of (i) whether the Company has sufficient authorized shares of
Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5.
<B><U>Calculations</U></B>. All calculations under this Section &lrm;3 shall be made to the nearest fraction of a cent as in the initial
Exercise Price or the nearest 1/100th of a share, as the case may be. For purposes of this Section &lrm;3, the number of shares of Common
Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury
shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6.
<B><U>Notice to Holder</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6.1.
<B><U>Adjustment to Exercise Price</U></B>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section &lrm;3,
the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6.2.
<B><U>Notice to Allow Exercise by Holder</U></B>. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
(C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least twenty (20) Calendar Days prior to the applicable record
or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock
of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date
as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of Common Stock for
securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate
action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material,
non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the
date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Transfer
                                            of Warrant</U>.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.
<B><U>Transferability</U></B>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto as <U>Exhibit &lrm;2.7.6</U> duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as
applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new
Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned
this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days after the date
on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.
<B><U>New Warrants</U></B>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section &lrm;4.1, as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be
divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial Issuance
Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.
<B><U>Warrant Register</U></B>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the &ldquo;<B><U>Warrant Register</U></B>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to
the Holder, and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Miscellaneous</U>.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.
<B><U>No Rights as Stockholder until Exercise; No Settlement in Cash</U>.</B> This Warrant does not entitle the Holder to any voting
rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section &lrm;2.7.1, except
as expressly set forth in Section &lrm;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo;
pursuant to Section &lrm;2.3or to receive cash payments pursuant to Section &lrm;2.7.1 and Section &lrm;2.7.4 herein, in no event shall
the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.
<B><U>Loss, Theft, Destruction or Mutilation of Warrant</U></B>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.
<B><U>Saturdays, Sundays, Holidays, etc</U>.</B> If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then such action may be taken, or such right may be exercised, on the next succeeding
Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4.
<B><U>Authorized Shares</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4.1.
<B><U>Reservation of Authorized and Unissued Shares</U></B>. The Company covenants that, while the Warrant is outstanding, it will reserve
from its authorized and unissued Common Stock a sufficient number of shares of Common Stock to provide for the issuance of the Warrant
Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall
constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of
the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant
Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading
Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise
of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment
for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable (which means that no
further sums are required to be paid by the holders thereof in connection with the issue thereof) and free from all taxes, liens and
charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue). If the Company does not have a sufficient number of authorized and unissued shares of Common Stock available to honor
the exercise of Warrants, the Company shall allocate the available number of Warrant Shares on a pro rata basis among all Holders exercising
Warrants, until such time as the Company has a sufficient number of authorized Common Stock to issue all Warrant Shares in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4.2.
<B><U>Noncircumvention</U></B>. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action,
including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking
of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount
payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or
appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of
this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public
regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4.3.
<B><U>Authorizations, Exemptions and Consents</U></B>. Before taking any action that would result in an adjustment in the number of Warrant
Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions
thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5.
<B><U>Governing Law</U></B>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of
the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers,
stockholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City
of Wilmington. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City
of Wilmington, Count of New Castle for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. Notwithstanding
the foregoing, nothing in this paragraph shall limit or restrict the federal district court in which a Holder may bring a claim under
the federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.
<B><U>Restrictions</U></B>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7.
<B><U>Nonwaiver and Expenses</U></B>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. No provision of this Warrant
shall be construed as a waiver by the Holder of any rights which the Holder may have under the federal securities laws and the rules
and regulations of the Commission thereunder. Without limiting any other provision of this Warrant or the Securities Purchase Agreement,
if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the
Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited
to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due
pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8.
<B><U>Notices</U></B>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 680 East Colorado Boulevard, Suite 180, Pasadena, CA 91101, Attention: Geordan Pursglove,
Chief Executive Officer, email address: g.pursglove@2gpgroup.com, or such other email address or address as the Company may specify for
such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder
shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each
Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries
hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered
via e-mail at the e-mail address set forth in this Section &lrm;5.8 prior to 5:30 p.m. (New York City time) on any date, (ii) the next
Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in
this Section &lrm;5.8 on a Calendar Day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii)
the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual
receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains,
material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the
Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9.
<B><U>Limitation of Liability</U></B>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10.
<B><U>Remedies</U></B>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11.
<B><U>Successors and Assigns</U></B>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.
<B><U>Amendment</U></B>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,
on the one hand, and a majority-in-interest of Holders of the Warrants, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13.
<B><U>Severability</U></B>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14.
<B><U>Headings</U></B>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[LIXT
Investor Registered Pre-Funded Warrant Signature Page Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[LIXT
Investor Registered Pre-Funded Warrant Signature Page]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Registered Pre-Funded Warrant to be executed by its officer thereunto duly authorized as
of the date first above indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIXTE
  BIOTECHNOLOGY HOLDINGS, INC.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geordan
  Pursglove</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
  Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
&lrm;2.1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIXTE
  BIOTECHNOLOGY HOLDINGS, INC.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
  lawful money of the United States.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
  permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in Section &lrm;2.3,
  to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
  set forth in Section &lrm;2.3.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[LIXT
Investor Registered Pre-Funded Warrant Exercise Notice &ndash; Investor Signature Page]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Investing Entity: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    of Authorized Signatory of Investing Entity:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Authorized Signatory: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Authorized Signatory: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
&lrm;2.7.6</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase
shares of Common Stock.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><IMG SRC="ex5-1_001.jpg" ALT="" style="width:250px"></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 38%"><P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TroyGould
                                            pc</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1801
    Century Park East, 16th Floor</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
    Angeles, California 90067-2367</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel</B>
    (310) 553-4441 | <B>Fax</B> (310) 201-4746</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.troygould.com</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TroyGould
    PC</B>  &#9679; (310) 789-1290 &#9679; dficksman@troygould.com</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    No. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
8, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte
Biotechnology Holdings, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">680
E. Colorado Boulevard, Suite 180</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pasadena,
CA 91101</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Ladies and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to Lixte Biotechnology Holdings, Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), relating
to the offering by the Company of an aggregate of 210,675 shares of Common Stock (the &ldquo;<B><I>Shares</I></B>&rdquo;); and Pre-Funded
Warrants (the &ldquo;<B><I>Pre</I></B>-<B><I>Funded Warrants</I></B> &ldquo;) to purchase an aggregate of 763, 351 shares of Common Stock
(the &ldquo;<B><I>Pre-Funded Warrant Shares</I></B>&rdquo;). The Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares are
referred to herein collectively as the &ldquo;<B><I>Securities</I></B>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed
herein as to any matter pertaining other than as expressly stated herein with respect to the issue of the Shares, Pre-Funded Warrants
and Pre-Funded Warrant Shares. The Securities are being sold pursuant to a Purchase Agreement dated July 3,2025 entered into between
the Company and the purchasers identified on the signature page thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with our opinion, we have examined the form of Pre-Funded Warrant and such other documents, corporate records and instruments,
and have examined such laws and regulations, as we have deemed necessary for the purposes of this opinion. In making our examination,
we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity with
the originals of all documents submitted to us as copies and the legal capacity of all natural persons. As to matters of fact material
to our opinions in this letter, we have relied on certificates and statements from officers and other employees of the Company, public
officials and other appropriate persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing and subject to the qualifications set forth below, we are of the opinion that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The Shares, when issued by the Company against payment therefor in the circumstances contemplated by the Purchase Agreement, will have
been duly authorized for issuance by all necessary corporate action by the Company, and will be validly issued, fully paid and non-assessable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT="" style="width:150px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte Biotechnology Holdings, Inc.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 8, 2025</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 2</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The Pre-Funded Warrants when issued by the Company against payment therefor , will have been duly authorized by all necessary corporate
action of the Company and will constitute a valid and binding agreement of the Company enforceable against the Company in accordance
with its terms;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
The Pre-Funded Warrant Shares issuable upon exercise of the Pre-Funded Warrants when issued by the Company against payment therefor (not
less than par value) will have been duly authorized by all necessary corporate action of the Company, and will be validly issued, fully
paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinions set forth above are subject to the following qualifications:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
The opinion expressed herein with respect to the legality, validity, binding nature and enforceability of the Pre-Funded Warrants is
subject to (i) applicable laws relating to bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer or other similar laws
affecting creditors&rsquo; rights generally, whether now or hereafter in effect and (ii) general principles of equity, including, without
limitation, concepts of materiality, laches, reasonableness, good faith and fair dealing and the principles regarding when injunctive
or other equitable remedies will be available (regardless of whether considered in a proceeding at law or in equity).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
The foregoing opinions are limited to the General Corporation Law of Delaware (which includes those statutory provisions and all applicable
provisions of the Delaware Constitution and the reported judicial decisions interpreting such laws) and the federal laws of the United
States of America, and we express no opinion as to the laws of any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinions expressed in this opinion letter are as of the date of this opinion letter only and as to laws covered hereby only as they are
in effect on that date, and we assume no obligation to update or supplement such opinion to reflect any facts or circumstances that may
come to our attention after that date or any changes in law that may occur or become effective after that date. The opinions herein are
limited to the matters expressly set forth in this opinion letter, and no opinion or representation is given or may be inferred beyond
the opinions expressly set forth in this opinion letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TroyGould
PC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<B><U>Agreement</U></B>&rdquo;) is dated as of July 3, 2025, between Lixte Biotechnology Holdings,
Inc., a Delaware corporation (the &ldquo;<B><U>Company</U></B>&rdquo;), and each purchaser identified on the signature pages hereto (including
their respective successors and assigns, each, a &ldquo;<B><U>Purchaser</U></B>&rdquo; and collectively, the &ldquo;<B><U>Purchasers</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
subject to the terms and conditions set forth in this Agreement and pursuant to an effective shelf registration statement under Section
4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;<B><U>Securities Act</U></B>&rdquo;), and Rule 506 promulgated thereunder,
the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the
Company, securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE, IN CONSIDERATION</B> of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the
receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser, severally and not jointly, agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Definitions</U></B>.
                                            In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement,
                                            the following terms have the meanings set forth in this Section 1:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1. &ldquo;<B><U>Acquiring
Person</U></B>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2. &ldquo;<B><U>Action</U></B>&rdquo;
shall have the meaning ascribed to such term in Section 3.1.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3. &ldquo;<B><U>Affiliate</U></B>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4. &ldquo;<B><U>Agreement</U></B>&rdquo;
shall have the meaning ascribed to such term in the preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5. &ldquo;<B><U>BHCA</U></B>&rdquo;
shall have the meaning ascribed to such term in Section 3.1.36.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6. &ldquo;<B><U>Board
of Directors</U></B>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7. &ldquo;<B><U>Business
Day</U></B>&rdquo; means a Calendar Day other than a Saturday, Sunday or any other Calendar Day which is a federal legal holiday in the
United States or any Calendar Day on which the commercial banks in the City of New York are required by law or other governmental action
to close, provided that the commercial banks in the City of New York shall not be deemed to be required to be closed due to a &ldquo;stay
at home,&rdquo; &ldquo;shelter in place,&rdquo; &ldquo;non-essential employee&rdquo; or similar orders or restrictions or the closure
of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including
for wire transfers) of commercial banks in the City of New York generally are open for use by customers on such Calendar Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8. &ldquo;<B><U>Calendar
Day</U></B>&rdquo; means each and every day of the week (Sunday, Monday, Tuesday, Wednesday, Thursday, Friday and Saturday).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9. &ldquo;<B><U>Closing</U></B>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10. &ldquo;<B><U>Closing
Date</U></B>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second (2nd) Trading
Day following the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11. &ldquo;<B><U>Code</U></B>&rdquo;
means the Internal Revenue Code of 1986, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12. &ldquo;<B><U>Commission</U></B>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13. &ldquo;<B><U>Common
Stock</U></B>&rdquo; means the common stock of the Company, $0.0001 par value per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14. &ldquo;<B><U>Common
Stock Equivalents</U></B>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15. &ldquo;<B><U>Company</U></B>&rdquo;
shall have the meaning ascribed to such term in the preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16. &ldquo;<B><U>Company
Counsel</U></B>&rdquo; means with respect to U.S. federal securities law and New York law and Delaware law, TroyGould PC, 1801 Century
Park East, 16th Floor, Los Angeles, CA 90067.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.17. &ldquo;<B><U>Disclosure
Schedules</U></B>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18. &ldquo;<B><U>Disclosure
Time</U></B>&rdquo; means, (i) if this Agreement is signed on a Calendar Day that is not a Trading Day or after 9:00 a.m. (New York City
time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following
the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between
midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on
the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.19. &ldquo;<B><U>DVP</U></B>&rdquo;
shall have the meaning ascribed to such term in Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20. &ldquo;<B><U>Evaluation
Date</U></B>&rdquo; shall have the meaning ascribed to such term in Section 3.1.14.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.21. &ldquo;<B><U>Exchange
Act</U></B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22. &ldquo;<B><U>FCPA</U></B>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.23. &ldquo;<B><U>FDA</U></B>&rdquo;
shall have the meaning ascribed to such term in Section 3.1.39.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.24. &ldquo;<B><U>FDCA</U></B>&rdquo;
shall have the meaning ascribed to such term in Section 3.1.39.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.25. &ldquo;<B><U>Federal
Reserve</U></B>&rdquo; shall have the meaning ascribed to such term in Section 3.1.36.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26. &ldquo;<B><U>GAAP</U></B>&rdquo;
shall have the meaning ascribed to such term in Section 3.1.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.27. &ldquo;<B><U>Indebtedness</U></B>&rdquo;
shall have the meaning ascribed to such term in Section 3.1.22.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.28. &ldquo;<B><U>Intellectual
Property Rights</U></B>&rdquo; shall have the meaning ascribed to such term in Section 3.1.11.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.29. &ldquo;<B><U>IT
Systems and Data</U></B>&rdquo; shall have the meaning ascribed to such term in Section 3.1.40.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.30. &ldquo;<B><U>Liens</U></B>&rdquo;
means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.31. &ldquo;<B><U>Lock-Up
Agreement</U></B>&rdquo; means each Lock-Up Agreement, dated as of the date hereof, by and between the Company and each of the directors,
executive officers, employees and stockholders holding at least ten percent (10%) of the outstanding shares of Common Stock, in the form
of <B><U>Exhibit 1.31</U></B> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32. &ldquo;<B><U>Material
Adverse Effect</U></B>&rdquo; shall have the meaning assigned to such term in Section 3.1.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33. &ldquo;<B><U>Material
Permits</U></B>&rdquo; shall have the meaning ascribed to such term in Section 3.1.9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.34. &ldquo;<B><U>Money
Laundering Laws</U></B>&rdquo; shall have the meaning ascribed to such term in Section 3.1.37.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.35. &ldquo;<B><U>OFAC</U></B>&rdquo;
shall have the meaning ascribed to such term in Section 3.1.34.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.36. &ldquo;<B><U>Per
Share Purchase Price</U></B>&rdquo; equals $1.54 (less $0.00001 for each Pre-Funded Warrant), subject to adjustment for reverse and forward
stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.37. &ldquo;<B><U>Person</U></B>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.38. &ldquo;<B><U>PFIC</U></B>&rdquo;
shall have the meaning ascribed to such term in Section 4.14.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.39. &ldquo;<B><U>Pharmaceutical
Product</U></B>&rdquo; shall have the meaning ascribed to such term in Section 3.1.39.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.40. &ldquo;<B><U>Placement
Agent</U></B>&rdquo; means Spartan Capital Securities, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41. &ldquo;<B><U>Placement
Agent Agreement</U></B>&rdquo; means the placement agent agreement, dated on or about the date hereof, between the Company and the Placement
Agent relating to the purchase and sale of the Securities under this Agreement and the purchase and sale of Securities to other accredited
investors pursuant to the terms of such Placement Agent Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.42. &ldquo;<B><U>Pre-Funded
Warrants</U></B>&rdquo; means the pre-funded Common Stock purchase warrants, in the form of <B><U>Exhibit 1.42.1</U></B> attached
hereto delivered to the Purchasers at the Closing in accordance with Section 2.2.1 hereof, which Pre-Funded Warrants shall be exercisable
immediately and shall expire when exercised in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.43. &ldquo;<B><U>Proceeding</U></B>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.44. &ldquo;<B><U>Prospectus</U></B>&rdquo;
means the final base prospectus filed for the Shelf Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.45. &ldquo;<B><U>Prospectus
Supplement</U></B>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with
the Commission and delivered by the Company to each Purchaser at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46. &ldquo;<B><U>Purchaser</U></B>&rdquo;
shall have the meaning ascribed to such term in the preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.47. &ldquo;<B><U>Purchaser
Party</U></B>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.48. &ldquo;<B><U>Release
Date</U></B>&rdquo; means the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.49. &ldquo;<B><U>Required
Approvals</U></B>&rdquo; shall have the meaning ascribed to such term in Section 3.1.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.50. &ldquo;<B><U>Rule
144</U></B>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.51. &ldquo;<B><U>Rule
424</U></B>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.52. &ldquo;<B><U>SEC
Reports</U></B>&rdquo; shall have the meaning ascribed to such term in Section 3.1.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.53. &ldquo;<B><U>Securities</U></B>&rdquo;
means the Shares, the Pre-Funded Warrants and the Warrant Shares purchased pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.54. &ldquo;<B><U>Securities
Act</U></B>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.55. &ldquo;<B><U>Shares</U></B>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement, but excluding the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.56. &ldquo;<B><U>Shelf
Registration Statement</U></B>&rdquo; means the effective registration statement on Form S-3 with Commission (File No. 333-278874), including
all information, documents and exhibits filed with or incorporated by reference into such registration statement, which registers the
sale of the Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.57. &ldquo;<B><U>Short
Sales</U></B>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not
be deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.58. &ldquo;<B><U>Subscription
Amount</U></B>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for the Securities purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.59. &ldquo;<B><U>Subsidiary</U></B>&rdquo;
means any subsidiary of the Company as set forth in Schedule 3.1.1 and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.60. &ldquo;<B><U>Trading
Day</U></B>&rdquo; means a Calendar Day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.61. &ldquo;<B><U>Trading
Market</U></B>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the
date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York
Stock Exchange, the OTCQB<SUP>&reg;</SUP> Venture Market, the OTCQX<SUP>&reg;</SUP> Best Market, or the Pink<SUP>&reg;</SUP> Open Market
(or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.62. &ldquo;<B><U>Transaction
Documents</U></B>&rdquo; means this Agreement, the Lock-Up Agreements and all exhibits and schedules thereto and hereto and any other
documents or agreements executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.63. &ldquo;<B><U>Transfer
Agent</U></B>&rdquo; means Computershare Trust Company, N.A., the current transfer agent of the Company, with a mailing address of 150
Royall Street, Suite 101. Canton, MA 02021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.64. &ldquo;<B><U>Warrants</U></B>&rdquo;
means the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.65. &ldquo;<B><U>Warrant
Shares</U></B>&rdquo; means the shares of Common Stock underlying the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Purchase
                                            and Sale</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1. <B><U>Closing</U></B>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery
of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase,
up to an aggregate of approximately $1.5 million of Shares and Warrants; <U>provided</U>, <U>however</U>, that a Purchaser in its sole
and absolute discretion, may elect to purchase Pre-Funded Warrants in lieu of Shares in such manner to result in the same aggregate purchase
price being paid by such Purchaser less $0.00001 per Pre-Funded Warrant. Each Purchaser shall make such Purchaser&rsquo;s Subscription
Amount as set forth on the signature page hereto executed by such Purchaser available to be delivered to the Company (or its designee)
via DVP (as defined below), and the Company shall deliver to each Purchaser its respective Securities, as determined pursuant to Section
 2.2.1, and the Company and each Purchaser shall deliver the other items set forth in Section 2.2.2 deliverable at the Closing.
Upon satisfaction of the covenants and conditions set forth in Sections 2.3.1 and 2.3.2, the Closing shall occur at the offices
of counsel to the Placement Agent or such other location (or remotely by electronic means) as the parties shall mutually agree. Unless
otherwise directed by the Placement Agent, settlement of the Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<B><U>DVP</U></B>&rdquo;)
(i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo; names and addresses and released by
the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement
Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement
Agent (or its clearing firm) by wire transfer to the Company). Notwithstanding anything herein to the contrary, if at any time on or
after the time of execution of this Agreement by the Company and an applicable Purchaser, through and including the time immediately
prior to the Closing (the &ldquo;<B><U>Pre-Settlement Period</U></B>&rdquo;), if such Purchaser sells to any Person all, or any portion,
of any Shares to be issued hereunder to such Purchaser at the Closing (collectively, the &ldquo;<B><U>Pre-Settlement Shares</U></B>&rdquo;),
such Purchaser shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to
be unconditionally bound to purchase, and the Company shall be deemed unconditionally bound to sell to such Purchaser, such Pre-Settlement
Shares at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior
to the Company&rsquo;s receipt of the purchase price for such Pre-Settlement Shares hereunder, and provided further that the Company
hereby acknowledges and agrees that the foregoing shall not constitute a representation or covenant by such Purchaser as to whether or
not such Purchaser will elect to sell any Pre-Settlement Shares during the Pre-Settlement Period. The decision to sell any Pre-Settlement
Shares will be made in the sole discretion of such Purchaser from time to time, including during the Pre-Settlement Period. Notwithstanding
the foregoing, with respect to any Notice(s) of Exercise (as defined in the Prefunded Warrants) delivered on or prior to 2:00 p.m. (New
York City time) on the Closing Date, which may be delivered at any time after the time of execution of the this Agreement, the Company
agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing
Date shall be the Warrant Share Delivery Date (as defined in the Prefunded Warrants) for purposes hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2. <B><U>Deliveries</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1. The
Company shall deliver or cause to be delivered to each Purchaser or the Placement Agent, as appropriate, the following at the times stated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.1 on
the date hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.1.1. this
Agreement duly executed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.1.2. the
Placement Agent Agreement, duly executed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.1.3. a
certificate executed by the Chief Financial Officer of the Company in customary form reasonably satisfactory to the Placement Agent and
its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.1.4. the
Lock-Up Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.2 on
or prior to the Closing Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.2.1. a
legal opinion and negative assurance letter of Company Counsel, addressed to the Placement Agent and the Purchasers, in form and substance
reasonably acceptable to the Placement Agent and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.2.2.
for each Purchaser of Pre-Funded Warrants pursuant to Section 2.1, a Pre-Funded Warrant registered in the name of such Purchaser to
purchase up to a number of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to
Pre-Funded Warrants divided by the Per Unit Purchase Price, with an exercise price equal to $0.00001, subject to adjustment as
provided therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.2.3. subject
to the provisions of Section 2.1 regarding settlement via DVP, the Company&rsquo;s wire instructions, on Company letterhead and executed
by the Chief Executive Officer or Chief Financial Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.2.4. a
duly executed and delivered Officers&rsquo; Certificate, in customary form reasonably satisfactory to the Placement Agent and its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.2.5. a
cold comfort letter from the Company&rsquo;s auditor, addressed to the Placement Agent in form and substance reasonably satisfactory
in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.2.6. the
Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.2. Each
Purchaser, and the Placement Agent, as applicable, shall deliver or cause to be delivered to the Company or the Company Counsel, as applicable,
the following at the times stated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.2.1 on
the date hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.2.1.1. this
Agreement duly executed by such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.2.1.2. the
Placement Agent Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.2.2 on
or prior to the Closing Date, such Purchaser&rsquo;s Subscription Amount shall be made available for DVP settlement with the Company
or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3. <B><U>Closing
Conditions</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.1. The
obligations of the Company hereunder in connection with the Closing are subject to each of the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.1.1 the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as
of a specific date therein in which case they shall be accurate as of such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.1.2 all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.1.3 the
delivery by each Purchaser of the items set forth in Section 2.2.2 of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2. The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to each of the following conditions being
met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2.1 the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of
a specific date therein in which case they shall be accurate as of such date).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2.2 all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2.3 the
delivery by the Company of the items set forth in Section <I> </I>2.2.1 of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2.4 there
shall have been no Material Adverse Effect with respect to the Company since the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2.5 from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Representations
                                            and Warranties</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1. <B><U>Representations
and Warranties of the Company</U></B>. The Company hereby makes the following representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1. <B><U>Subsidiaries</U></B>.
All of the direct and indirect subsidiaries of the Company are set forth on Exhibit 21.1 to the Company&rsquo;s Annual Report on Form
10-K. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear
of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid,
non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries,
all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.2. <B><U>Organization
and Qualification</U></B>. Each of the Company and its operating Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could
not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<B><U>Material
Adverse Effect</U></B>&rdquo;; provided, however, that &ldquo;<B><U>Material Adverse Effect</U></B>&rdquo; shall not include any event,
occurrence, fact, condition or change, directly or indirectly, arising out of or attributable to: (i) the announcement, pendency or completion
of the transactions contemplated by the Transaction Documents or (ii) any action required or permitted by the Transaction Documents or
any action taken (or omitted to be taken) with the written consent of or at the written request of Purchaser). As to all Company and
Subsidiary power, authority and qualification, no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing
or seeking to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.3. <B><U>Authorization;
Enforcement</U></B>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other
than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or
upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.4. <B><U>No
Conflicts</U></B>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which
it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.5. <B><U>Filings,
Consents and Approvals</U></B>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person
in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required
pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement to the Shelf Registration
Statement, (iii) the notice and/or application(s) to each applicable Trading Market for the issuance and sale of the Securities and the
listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, (iv) the filing of Form D with
the Commission and such other filings as are required to be made under applicable state securities laws (the &ldquo;<B><U>Required Approvals</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1. <B><U>Issuance
of the Securities; Registration</U></B>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable (which means that no further sums are required to
be paid by the holders thereof in connection with the issue thereof), free and clear of all Liens imposed by the Company other than restrictions
on transfer provided for in the Transaction Documents and applicable law. The Warrant Shares, when issued in accordance with the terms
of the Transaction Documents, will be validly issued, fully paid and nonassessable (which means that no further sums are required to
be paid by the holders thereof in connection with the issue thereof), free and clear of all Liens imposed by the Company other than restrictions
on transfer provided for in the Transaction Documents and applicable law. As of the date hereof, the Company has reserved and the Company
shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for
the purpose of enabling the Company to issue Shares pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1. <B><U>Registration
Statement</U></B>. The Company has prepared and filed the Shelf Registration Statement in conformity with the requirements of the Securities
Act, which became effective on , including the Prospectus, and such amendments and supplements thereto as may have been required to the
date of this Agreement. The Shelf Registration Statement is effective under the Securities Act and no stop order preventing or suspending
the effectiveness of the Shelf Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission
and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company,
if required by the rules and regulations of the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule
424(b). At the time the Shelf Registration Statement and any amendments thereto became effective, at the date of this Agreement and at
the Closing Date, the Shelf Registration Statement and any amendments thereto conformed and will conform in all material respects to
the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments
or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed
and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. The Company was at the time of the filing of the Shelf Registration Statement eligible to
use Form S-1. The Company is eligible to use Form S-3 under the Securities Act and it meets the requirements with respect to the aggregate
market value of securities being sold pursuant to this offering and during the twelve (12) months prior to this offering, as set forth
in General Instruction I.B.1. of Form S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.2. <B><U>Capitalization</U></B>.
The capitalization of the Company as of the date hereof is as set forth on Schedule 3.1.1, which Schedule 3.1.1 shall also
include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof. Other
than as stated in Schedule 3.1.1, the Company has not issued any capital stock since its most recently filed periodic report under
the Exchange Act, other than pursuant to the exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance
of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or
exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No
Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions
contemplated by the Transaction Documents. Except as set forth in Schedule 3.1.1, or pursuant to this Agreement, there are no outstanding
options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights
or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares
of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company
or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any
Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or
other securities to any Person (other than the Purchasers). Except as set forth in Schedule 3.1.1, there are no outstanding securities
or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of
such security or instrument upon an issuance of securities by the Company or any Subsidiary. Except as set forth in Schedule 3.1.1,
there are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions,
and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound
to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo;
plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized,
validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of
such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No
further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities.
There are no stockholders&rsquo; agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital
stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.3. <B><U>SEC
Reports; Financial Statements</U></B>. The Company has filed all reports, schedules, forms, statements and other documents required to
be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and
the Prospectus Supplement, being collectively referred to herein as the &ldquo;<B><U>SEC Reports</U></B>&rdquo;) on a timely basis or
has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension.
As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange
Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial
statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the
rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been
prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved
(&ldquo;<B><U>GAAP</U></B>&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto, and fairly
present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof
and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial,
year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.4. <B><U>Material
Changes; Undisclosed Events, Liabilities or Developments</U></B>. Since the date of the latest audited financial statements included
within the SEC Reports, except as set forth on Schedule 3.1.4, (i) there has been no event, occurrence or development that has had
or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence
or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or
their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed
at least one (1) Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.5. <B><U>Litigation</U></B>.
Except as set forth in Schedule 3.1.5, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending
or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<B><U>Action</U></B>&rdquo;). None of the Actions set forth on Schedule 3.1.5, (i) adversely affects or
challenges the legality, validity or enforceability of any of the Transaction Documents or (ii) would, if there were an unfavorable decision,
have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer
thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws
or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the Commission involving the Company or any current or former director or officer of the Company, except in the
ordinary course of business that would not have a Material Adverse Effect. The Commission has not issued any stop order or other order
suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.6. <B><U>Labor
Relations</U></B>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the
Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.7. <B><U>Compliance</U></B>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii) is in violation of any judgment, decree, or order of any court, arbitrator or other governmental
authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including
without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety,
product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result
in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.8. <B><U>Environmental
Laws</U></B>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &ldquo;<B><U>Hazardous Materials</U></B>&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<B><U>Environmental Laws</U></B>&rdquo;);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.9. <B><U>Regulatory
Permits</U></B>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<B><U>Material
Permits</U></B>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation
or modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.10. <B><U>Title
to Assets</U></B>. The Company and the Subsidiaries have good and marketable title in fee simple to, or have valid and marketable rights
to lease or otherwise use, all real property and all personal property that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens that do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made in accordance with GAAP, and the payment of which is
neither delinquent nor subject to penalties. Neither the Company nor any of its Subsidiaries has received any written notice of any claim
of any sort that has been asserted by anyone adverse to the rights of the Company or its Subsidiaries under any of the leases or subleases
or licenses or with respect to the properties mentioned above, or affecting or questioning the rights of the Company or any Subsidiary
to the continued possession or use of the leased or subleased or licensed premises or the properties mentioned above, other than such
claims which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.11. <B><U>Intellectual
Property</U></B>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark
applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and
similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<B><U>Intellectual Property Rights</U></B>&rdquo;).
None of, and neither the Company nor any Subsidiary has received notice (written or otherwise) that any of, the Intellectual Property
Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years after the
date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements
included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate
or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect.
To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another
Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect
the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.12. <B><U>Insurance</U></B>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not
limited to, directors and officers insurance coverage in amount deemed prudent by the Company. Neither the Company nor any Subsidiary
has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.13. <B><U>Transactions
with Affiliates and Employees</U></B>. Except as set forth on Schedule 3.1.13, during the past three fiscal years and the subsequent
interim period through the date of this Agreement, none of the officers or directors of the Company or any Subsidiary and, to the knowledge
of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any
Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing
for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of
money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge
of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director,
trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for
services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock
option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.14. <B><U>Sarbanes-Oxley;
Internal Accounting Controls</U></B>. The Company and the Subsidiaries are in material compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. Except as set forth on
Schedule 3.1.14, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable
assurance that: (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information
required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized
and reported, within the time periods specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have
evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period
covered by the most recently filed periodic report under the Exchange Act (such date, the &ldquo;<B><U>Evaluation Date</U></B>&rdquo;).
The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about
the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation
Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the
Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial
reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.15. <B><U>Certain
Fees</U></B>. Except for the fees and expenses of the Placement Agent, no brokerage or finder&rsquo;s fees or commissions are or will
be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this
Section 3.1.15 that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.16. <B><U>Investment
Company</U></B>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not
be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.17. <B><U>Registration
Rights</U></B>. Except as disclosed on Schedule 3.1.17, no Person has any right to cause the Company or any Subsidiary to effect
the registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.18. <B><U>Listing
and Maintenance Requirements</U></B>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the
Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the
Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such
registration. Except as disclosed in Schedule 3.1.18 and in the Company&rsquo;s securities filings, including the current Shelf
Registration Statement, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which
the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance
requirements of such Trading Market. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company
or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such
other established clearing corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.19. <B><U>Application
of Takeover Protections</U></B>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their
obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s
issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.20. <B><U>Disclosure</U></B>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information
that it believes constitutes or might constitute material, non-public information. The Company understands and confirms that the Purchasers
will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by
or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions
contemplated hereby, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading.
The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order
to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company
acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.21. <B><U>No
Integrated Offering</U></B>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of any
such securities under the Securities Act, or (ii) any applicable stockholder approval provisions of any Trading Market on which any of
the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.22. <B><U>Solvency</U></B>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds the amount
that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known contingent
liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its business as
now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of
the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the
current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year after the Closing Date. Schedule 3.1.22 sets forth as of the date hereof all outstanding
secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For
the purposes of this Agreement, &ldquo;<B><U>Indebtedness</U></B>&rdquo; means (x) any liabilities for borrowed money or amounts owed
in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements
and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s
consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection
or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due
under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to
any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.23. <B><U>Tax
Status</U></B>. Except as disclosed in Schedule 3.1.23, the Company and its Subsidiaries each (i) has made or filed all material
United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by
any jurisdiction to which it is subject, (ii) has paid all material taxes and other governmental assessments and charges that are material
in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably
adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply.
There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the
Company or of any Subsidiary know of no basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.24. <B><U>No
General Solicitation</U></B>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and
certain other &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.25. <B><U>Foreign
Corrupt Practices Act</U></B>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent
or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds,
(iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of
which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.26. <B><U>Accountants</U></B>.
The Company&rsquo;s accounting firm is Weinberg &amp; Company, P.A., with offices at 1925 Century Park East,, Suite 1120, Los Angeles,
CA 90067. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by
the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company&rsquo;s Annual
Report for the now current fiscal year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.27. <B><U>No
Disagreements with Accountants and Lawyers</U></B>. There are no disagreements of any kind presently existing, or reasonably anticipated
by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company and the Company
is current with respect to any fees owed to its accountants and lawyers which could affect the Company&rsquo;s ability to perform any
of its obligations under any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.28. <B><U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U></B>. The Company acknowledges and agrees that each of the Purchasers is acting
solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.29. <B><U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U></B>. Notwithstanding anything in this Agreement or elsewhere herein to the contrary
(except for Sections 3.2.7 and 4.12 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers
has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities
of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified
term, (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales
or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly-traded securities, (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
Common Stock and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party
in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage
in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the
periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities
(if any) could reduce the value of the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging
activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any
of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.30. <B><U>Regulation
M Compliance</U></B>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any
action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&rsquo;s placement agent in connection
with the placement of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.31. <B><U>Officers&rsquo;
Certificate</U></B>. Any certificate signed by any duly authorized officer of the Company and delivered to the Purchasers shall be deemed
a representation and warranty by the Company to the Purchasers as to the matters covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.32. <B><U>D&amp;O
Questionnaires</U></B>. To the Company&rsquo;s knowledge, all information contained in the questionnaires most recently completed by
each of the Company&rsquo;s directors and officers and beneficial owner of 5% or more of the shares of Common Stock or Common Stock Equivalents
is true and correct in all respects and the Company has not become aware of any information which would cause the information disclosed
in such questionnaires become inaccurate and incorrect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.33. <B><U>Stock
Option Plans</U></B>. Each stock option granted by the Company under the Company&rsquo;s stock option plan, if any, was granted (i) in
accordance with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market
value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted
under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no
Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with,
the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results
or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.34. <B><U>Office
of Foreign Assets Control</U></B>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer,
agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (&ldquo;<B><U>OFAC</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.35. <B><U>U.S.
Real Property Holding Corporation</U></B>. The Company is not and has never been a U.S. real property holding corporation within the
meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.36. <B><U>Bank
Holding Company Act</U></B>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act
of 1956, as amended (the &ldquo;<B><U>BHCA</U></B>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System
(the &ldquo;<B><U>Federal Reserve</U></B>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly
or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or
more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company
nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that
is subject to the BHCA and to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.37. <B><U>Money
Laundering</U></B>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<B><U>Money Laundering Laws</U></B>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.38. <B><U>Other
Covered Persons</U></B>. Other than the Placement Agent, the Company is not aware of any person that has been or will be paid (directly
or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.39. <B><U>FDA</U></B>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<B><U>FDA</U></B>&rdquo;) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<B><U>FDCA</U></B>&rdquo;) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<B><U>Pharmaceutical
Product</U></B>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter
or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and
promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company
or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of
its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries,
and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of
the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations
of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United
States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving
or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.40. <B><U>Cybersecurity</U></B>.
(i) (a) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s
information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees,
suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;<B><U>IT
Systems and Data</U></B>&rdquo;) and (b) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event
or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii)
the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and
regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating
to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification, except, in the case of clauses (i) and (ii) herein, as would not, individually or in the aggregate, have a Material
Adverse Effect; (iii) the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain
and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems
and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry
standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.41. <B><U>Separate
and Independent Purchasers</U></B>. The Company further (a) represents and warrants and acknowledges and agrees that, to the knowledge
of the Company (i) each Purchaser is participating in the offering of Securities contemplated hereby separately and independently of
each other Purchaser, (ii) no Purchaser has communicated directly with any other Purchaser, (iii) all communications by each Purchaser
concerning the Transaction Documents and the transactions contemplated thereby and any matters related thereto were solely conducted
separately and independently with the Placement Agent without the involvement or inclusion of any other Purchaser and (iv) the Purchasers
do not constitute a &ldquo;group&rdquo; as that term is used under Section 13(d) of the Exchange Act, and (b) covenants and agrees not
to take a position to the contrary to the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2. <B><U>Representations
and Warranties of the Purchasers</U></B>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of
the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall
be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.1. <B><U>Organization;
Authority</U></B>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the law of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the legal, valid and binding obligation of such Purchaser, enforceable against it in accordance with its terms, except (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.2. <B><U>Own
Account</U></B>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty
shall not limit such Purchaser&rsquo;s right to sell the Securities pursuant to a registration statement or otherwise in compliance with
applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.3. <B><U>Purchaser
Status</U></B>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which
it exercises any Warrants, it will be either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3),
(a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo; as defined
in Rule 144A(a)(1) under the Securities Act. Such Purchaser hereby represents that neither such Purchaser nor any of its Rule 506(d)
Related Parties (as defined below) is a &ldquo;bad actor&rdquo; within the meaning of Rule 506(d) promulgated under the Securities Act.
For purposes of this Agreement, &ldquo;Rule 506(d) Related Party&rdquo; shall mean a person or entity covered by the &ldquo;Bad Actor
disqualification&rdquo; provision of Rule 506(d) of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.4. <B><U>Experience
of Such Purchaser</U></B>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in
the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an
investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.5. <B><U>General
Solicitation</U></B>. Such Purchaser is not, to such Purchaser&rsquo;s knowledge, purchasing the Securities as a result of any advertisement,
article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over
television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.6. <B><U>Access
to Information</U></B>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all
exhibits and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the
Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither
the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect
to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes
any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public
information with respect to the Company which such Purchaser agrees need not be and has not been provided to it (other than with respect
to the transactions contemplated by the Transaction Documents). In connection with the issuance of the Securities to such Purchaser,
neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.7. <B><U>Certain
Transactions and Confidentiality</U></B>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor
has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases
or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first
received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms
of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the
case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other
portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to
other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors,
partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures
made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing,
for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.8. <B><U>No
Intent to Effect a Change of Control</U></B>. Such Purchaser has no present intent to effect a &ldquo;change of control&rdquo; of the
Company as such term is interpreted and understood under the rules promulgated pursuant to Section 13(d) of the 1934 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Other
                                            Agreements of the Parties</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1. <B><U>Warrant
Shares</U></B>. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover
the issuance or resale of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares issued pursuant
to any such exercise shall be issued free of all legends. If at any time following the date hereof the Shelf Registration Statement (or
any subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available
for the sale or resale of the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that such registration
statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again
and available for the sale or resale of the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability
of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in compliance with applicable federal and state securities
laws). The Company shall use best efforts to keep a registration statement (including the Shelf Registration Statement) registering the
issuance or resale of the Warrant Shares effective during the term of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2. <B><U>Furnishing
of Information; Public Information</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.1. Until
no Purchaser owns any Securities and the Common Warrants have terminated, the Company covenants to maintain the effectiveness of the
registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to use reasonable best efforts to timely file (or
obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after
the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3. <B><U>Integration</U></B>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations
of any Trading Market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder
approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4. <B><U>Securities
Laws Disclosure; Publicity</U></B>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms
of the transactions contemplated hereby, and (b) file, within the time required by the Exchange Act, a Current Report on Form 8-K, including
the Transaction Documents as exhibits thereto, with the Commission. From and after the issuance of such press release, the Company represents
to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the
Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents (including, without limitation,
the Placement Agent) in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance
of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement,
whether written or oral, between the Company, any of its Subsidiaries, or any of their respective officers, directors, agents (including,
without limitation, the Placement Agent), employees or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates
on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Purchaser shall
be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall consult
with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor
any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company,
with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release
of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case
the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding
the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing
with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) to the
extent required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to
the extent such disclosure is required by law or Trading Market regulations, in which such cases the Company shall (x) obtain prior advice
of competent counsel that such disclosure is required, (y) provide the Purchasers with prior notice of such disclosure permitted under
this Section 4.4 and (z) reasonably cooperate with such Purchasers regarding such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5. <B><U>Stockholder
Rights Plan</U></B>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any
Purchaser is an &ldquo;<B><U>Acquiring Person</U></B>&rdquo; under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under
the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6. <B><U>Non-Public
Information</U></B>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such
information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall
not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents,
employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees
or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to
applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public
information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice
with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying
on the foregoing covenant in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7. <B><U>Use
of Proceeds</U></B>. The Company shall use the net proceeds from the sale of the Securities hereunder for general corporate purposes
(which for the avoidance of doubt may include acquisitions, in the Company&rsquo;s discretion), including working capital. The Company
shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment of trade payables
in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption of any shares of Common Stock or
Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8. <B><U>Indemnification
of each Purchaser</U></B>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and
its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;<B><U>Purchaser Party</U></B>&rdquo;) harmless from
any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid
in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer
or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the
Company in this Agreement or in the other Transaction Documents, or (b) any action instituted against the Purchaser Parties in any capacity
(including a Purchaser Party&rsquo;s status as an investor), or any of them or their respective Affiliates, by the Company or any stockholder
of the Company who is not an Affiliate of such Purchaser Party, arising out of or relating to any of the transactions contemplated by
the Transaction Documents. For the avoidance of doubt, the indemnification provided herein is intended to, and shall also cover, direct
claims brought by the Company against the Purchaser Parties; provided, however, that such indemnification shall not cover any loss, claim,
damage or liability to the extent it is finally judicially determined to be attributable to such Purchaser Party&rsquo;s material breach
of any of the representations, warranties or covenants made by such Purchaser Party in any Transaction Document or any conduct by such
Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct. If any action shall
be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall
promptly notify the Company in writing, and, except with respect to direct claims brought by the Company, the Company shall have the
right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party
shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses
of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically
authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ
counsel or (iii) in such action there is, in the reasonable opinion of counsel to the applicable Purchaser Party (which may be internal
counsel), a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in
which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company
will not be liable to any Purchaser Party under this Agreement for any settlement by a Purchaser Party effected without the Company&rsquo;s
prior written consent, which shall not be unreasonably withheld or delayed. In addition, if any Purchaser Party takes actions to collect
amounts due under any Transaction Documents or to enforce the provisions of any Transaction Documents, then the Company shall pay the
costs incurred by such Purchaser Party for such collection, enforcement or action, including, but not limited to, attorneys&rsquo; fees
and disbursements. The indemnification and other payment obligations required by this Section 4.8 shall be made by periodic payments
of the amount thereof during the course of the investigation, defense, collection, enforcement or action, as and when bills are received
or are incurred; provided, however, that if any Purchaser Party is finally judicially determined not to be entitled to indemnification
or payment under this Section 4.8, such Purchaser Party shall promptly reimburse the Company for any payments that are advanced
under this sentence. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser
Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9. <B><U>Listing
of Common Stock</U></B>. The Company hereby agrees to use its best efforts to maintain the listing or quotation of the Common Stock on
the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of
the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such
Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will
then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of
the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take
all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects
with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees
to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing
corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing
corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10. <B><U>Certain
Transactions and Confidentiality</U></B>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither
it, nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short
Sales, of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such
time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions
contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4,
such Purchaser will maintain the confidentiality of the existence and terms of this transaction. Notwithstanding the foregoing and notwithstanding
anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation,
warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the
transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section
 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance
with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced
pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality
or duty not to trade in the securities of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors,
employees, agents or Affiliates after the issuance of the initial press release as described in Section 4.4. Notwithstanding the
foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect
to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11. <B><U>Capital
Changes</U></B>. Until the date that is sixty (60) days after the Date, the Company shall not undertake a reverse or forward stock split
or reclassification of the Common Stock without the prior written consent of the Purchasers holding a majority in interest of the Shares
and Pre-Funded Warrants, based on the initial Subscription Amounts hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12. <B><U>Acknowledgment
of Dilution</U></B>. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of
Common Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges that its obligations
under the Transaction Documents, including, without limitation, its obligation to issue the Shares and Warrant Shares pursuant to the
Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless
of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive effect that
such issuance may have on the ownership of the other stockholders of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13. <B><U>Lock-Up
Agreements</U></B>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements (and any lock-up
agreements contemplated in the Lock-Up Agreements) except to extend the term of the lock-up period and shall enforce the provisions of
each Lock-Up Agreement (and any lock-up agreements contemplated in the Lock-Up Agreements) in accordance with its terms. If any party
to a Lock-Up Agreement (and any lock-up agreements contemplated in the Lock-Up Agreements) breaches any provision of a Lock-Up Agreement,
the Company shall promptly use its best efforts to seek specific performance of the terms of such Lock-Up Agreement (and any lock-up
agreements contemplated in the Lock-Up Agreements).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14. <B><U>QEF
Election</U></B>. If a Purchaser so requests in writing for any taxable year of the Company, the Company, after consulting with its outside
accounting firm, shall within fifteen (15) Business Days notify such Purchaser in writing that either (A) neither the Company nor any
of its Subsidiaries was a &ldquo;passive foreign investment company&rdquo; as defined in Section 1297 of the Code (&ldquo;<B><U>PFIC</U></B>&rdquo;)
for such year, or (B) the Company and/or one or more of its Subsidiaries was a PFIC for such year, in which event the Company shall provide
to such Purchaser, upon the reasonable written request of such Purchaser, the information reasonably necessary to allow such Purchaser
to elect to treat each of the Company and any applicable Subsidiaries (if any), respectively, as a &ldquo;qualified electing fund&rdquo;
(within the meaning of Section 1295 of the Code for such year, including a &ldquo;PFIC Annual Information Statement&rdquo; as described
in Treasury Regulation Section 1.1295-1(g)(1) (or any successor Treasury Regulation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15. <B><U>Reservation
of Common Stock</U></B>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available
at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue
Shares pursuant to this Agreement and the maximum number of Warrant Shares pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16. <B><U>Exercise
Procedures</U></B>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the
Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the
Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to
exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms,
conditions and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Miscellaneous</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1. <B><U>Termination</U></B>.
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever
on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been
consummated on or before the fifth (5th) Trading Day following the date hereof; <U>provided</U>, <U>however</U>, that no such termination
will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2. <B><U>Fees
and Expenses</U></B>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without
limitation, any fees required for same-Calendar Day processing of any instruction letter delivered by the Company and any exercise notice
delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3. <B><U>Entire
Agreement</U></B>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement,
contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4. <B><U>Notices</U></B>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email
at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day,
(b) the next Trading Day after the time of transmission, if such notice or communication is delivered via email at the email address
as set forth on the signature pages attached hereto on a Calendar Day that is not a Trading Day or later than 5:30 p.m. (New York City
time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of transmittal, if sent by U.S. nationally recognized
overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices
and communications shall be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant to any
Transaction Document constitutes, or contains material, non-public information regarding the Company or any of the Subsidiaries, the
Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5. <B><U>Amendments;
Waivers</U></B>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares and Pre-Funded Warrants
based on the initial Subscription Amounts hereunder (or, prior to Closing, the Company and each Purchaser) or, in the case of a waiver,
by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver
disproportionately and adversely impacts a Purchaser (or multiple Purchasers), the consent of such disproportionately impacted Purchaser
(or multiple Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the
rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior
written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding
upon each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6. <B><U>Headings</U></B>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7. <B><U>Successors
and Assigns</U></B>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser
(other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns
or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities,
by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8. <B><U>No
Third-Party Beneficiaries</U></B>. The Placement Agent shall be the third party beneficiary of the representations and warranties of
the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended
for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any
provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9. <B><U>Governing
Law</U></B>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be
governed by and construed and enforced in accordance with the law of the State of Delaware without regard to the principles of conflicts
of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, stockholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of Wilmington, Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of Wilmington and County of New Castle for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction
Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition
to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the
non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10. <B><U>Survival</U></B>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11. <B><U>Execution</U></B>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. If any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo; format data
file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12. <B><U>Severability</U></B>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13. <B><U>Rescission
and Withdrawal Right</U></B>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of)
any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that, in the case of a rescission
of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such Shares and
the restoration of such Purchaser&rsquo;s right to acquire such Shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance
of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14. <B><U>Replacement
of Securities</U></B>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu
of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15. <B><U>Remedies</U></B>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and
hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law
would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16. <B><U>Payment
Set Aside</U></B>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or
a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17. <B><U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U></B>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For
reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through
the legal counsel to the Placement Agent. The legal counsel of the Placement Agent does not represent any of the Purchasers and only
represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the
convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood
and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser,
solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18. <B><U>Liquidated
Damages</U></B>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents
is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have
been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19. <B><U>Saturdays,
Sundays, Holidays, etc.</U></B> If the last or appointed Calendar Day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20. <B><U>Construction</U></B>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21. <B><U>WAIVER
OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH
KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND
EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[LIXT
Securities Purchase Agreement Signature Pages Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[LIXT
Securities Purchase Agreement &ndash; Company Signature Page]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIXTE
    BIOTECHNOLOGY HOLDINGS, INC.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Address
    for Notice:</U></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">680
    East Colorado Boulevard, Suite 180,<BR>
    Pasadena, CA 91101<BR>
    Attention: Geordan Pursglove<BR>
    Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    g.pursglove@2gpgroup.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geordan
    Pursglove</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[LIXT
Securities Purchase Agreement &ndash; Investor Signature Page]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned has caused this Securities Purchase Agreement to be duly executed by its authorized signatory as of
the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Purchaser:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    of Authorized Signatory of Purchaser:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    for Notice to Purchaser:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    for Delivery of Securities to Purchaser (if not same as address for notice):</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
    Amount:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of Common Stock:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-funded
    Warrants:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
    Ownership Blocker:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employer
    Identification Number:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
 1.31</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Form
of Lock-Up Agreement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
 1.42.1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Form
of Pre-Funded Warrant</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 40; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>ex10-2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-2_001.jpg" ALT="" style="width:350px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
3, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>PERSONAL
AND CONFIDENTIAL</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Geordan Pursglove, Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte
Biotechnology Holdings, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">680
East Colorado Boulevard, Suite 180</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pasadena,
CA 91101</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>LIXT
                                            | RD | Placement Agent Agreement</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Mr. Pursglove:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of this placement agent agreement (the &ldquo;<B><U>Agreement</U></B>&rdquo;) is to outline our agreement pursuant to which Spartan
Capital Securities, LLC (&ldquo;<B><U>Spartan</U></B>&rdquo;) will act as the placement agent on a &ldquo;best efforts&rdquo; basis in
connection with the proposed RD Offering (the &ldquo;<B><U>Placement</U></B>&rdquo;) by Lixte Biotechnology Holdings, Inc. (collectively,
with its subsidiaries and affiliates, the &ldquo;<B><U>Company</U></B>&rdquo;) of its shares of Common Stock or Pre-funded Warrants to
purchase shares of Common Stock in lieu of shares of Common Stock (the &ldquo;<B><U>Securities</U></B>&rdquo;). This Agreement sets forth
certain conditions and assumptions upon which the Placement is premised. The Company expressly acknowledges and agrees that Spartan&rsquo;s
obligations hereunder are on a reasonable &ldquo;best efforts&rdquo; basis only and that the execution of this Agreement does not constitute
a commitment by Spartan to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof
or the success of Spartan with respect to securing any other financing on behalf of the Company. The Company confirms that entry into
this Agreement and completion of the Placement with Spartan will not breach or otherwise violate the Company&rsquo;s obligations to any
other party or require any payments to such other party. For the sake of clarity, such obligations may include but not be limited to
obligations under an engagement letter, placement agency agreement, underwriting agreement, advisory agreement, right of first refusal,
tail fee obligation or other agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of our agreement are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Engagement</U></B>.
                                            The Company hereby engages Spartan, for the period beginning on the date hereof and July
                                            3, 2025 or upon the completion of the Placement, whichever is sooner (the &ldquo;<B><U>Engagement
                                            Period</U></B>&rdquo;), to act as the Company&rsquo;s exclusive investment bank in connection
                                            with the proposed Placement. During the Engagement Period or until the consummation of the
                                            Placement, and as long as Spartan is proceeding in good faith with preparations for the Placement,
                                            the Company agrees not to solicit, negotiate with or enter into any agreement with any other
                                            source of financing (whether equity, debt or otherwise), any underwriter, potential underwriter,
                                            placement agent, financial advisor, investment banking firm or any other person or entity
                                            in connection with an offering of the Company&rsquo;s debt or equity securities or any other
                                            financing by the Company. Spartan will use its reasonable &ldquo;best efforts&rdquo; to solicit
                                            offers to purchase the Securities from the Company on the terms, and subject to the conditions,
                                            set forth in the Prospectus (as defined below). Spartan shall use commercially reasonable
                                            efforts to assist the Company in obtaining performance by each Purchaser (as defined below)
                                            whose offer to purchase Securities has been solicited by Spartan, but Spartan shall not,
                                            except as otherwise provided in this Agreement, be obligated to disclose the identity of
                                            any potential purchaser or have any liability to the Company in the event any such purchase
                                            is not consummated for any reason. The Company acknowledges that under no circumstances will
                                            Spartan be obligated to underwrite or purchase any Securities for its own account and, in
                                            soliciting purchases of the Securities, Spartan shall act solely as an agent of the Company.
                                            The services provided pursuant to this Agreement shall be on an &ldquo;agency&rdquo; basis
                                            and not on a &ldquo;principal&rdquo; basis.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>The
                                            Placement</U></B>. The Placement is expected to consist of a sale of approximately $1.5 million
                                            of the Company&rsquo;s Securities. Spartan will act as placement agent for the Placement
                                            subject to, among other matters referred to herein and additional customary conditions, completion
                                            of Spartan&rsquo;s due diligence examination of the Company and its affiliates, listing approval
                                            by the Nasdaq Capital Market (&ldquo;<B><U>Exchange</U></B>&rdquo;) of the Securities to
                                            be issued, and the execution of a definitive Securities Purchase Agreement in connection
                                            with the Placement (the &ldquo;<B><U>Securities Purchase Agreement</U></B>&rdquo;). The actual
                                            size of the Placement, the precise number of Securities to be offered by the Company and
                                            the offering price will be the subject of continuing negotiations between the Company and
                                            the investors thereto. In connection with entry into the Securities Purchase Agreement, the
                                            Company (i) will meet with Spartan and its representatives to discuss such due diligence
                                            matters and to provide such documents as Spartan may require; (ii) will not file with the
                                            Commission any document regarding the Placement without the prior approval of Spartan and
                                            its counsel; (iii) will deliver to Spartan and the investors in the Placement such legal
                                            and accounting opinions and letters (including, without limitation, accounting comfort letters,
                                            legal opinions, negative assurance letters, good standing certificates and officers&rsquo;
                                            and secretary certificates) as Spartan may require, all in form and substance acceptable
                                            to Spartan and (iv) will ensure that Spartan is a third party beneficiary of all representations,
                                            warranties, covenants, closing conditions and deliverables in connection with the Placement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Placement
                                            Compensation</U></B>. The placement commission will be 8.0% for the Placement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Registration
                                            Statement</U></B>. To the extent the Company decides to proceed with the Placement, the Company
                                            will use its currently effective Registration Statement on Form S-3 (the &ldquo;<B><U>Registration
                                            Statement</U></B>&rdquo;) filed with the Securities and Exchange Commission (the &ldquo;<B><U>Commission</U></B>&rdquo;)
                                            a under the Securities Act of 1933, as amended (the &ldquo;<B><U>Securities Act</U></B>&rdquo;)
                                            and a prospectus included therein (the &ldquo;<B><U>Prospectus</U></B>&rdquo;) covering the
                                            resale of the Securities to be offered and sold in the Placement. The Registration Statement
                                            (including the Prospectus therein), and all amendments and supplements thereto, will be in
                                            form reasonably satisfactory to Spartan and counsel to Spartan. Other than any information
                                            provided by Spartan in writing specifically for inclusion in the Registration Statement or
                                            the Prospectus, the Company will be solely responsible for the contents of its Registration
                                            Statement and Prospectus and any and all other written or oral communications provided by
                                            or on behalf of the Company to any actual or prospective investor of the Securities, and
                                            the Company represents and warrants that such materials and such other communications will
                                            not, as of the date of the offer or sale of the Securities, contain any untrue statement
                                            of a material fact or omit to state a material fact required to be stated therein or necessary
                                            in order to make the statements therein, in light of the circumstances under which they were
                                            made, not misleading. If at any time prior to the completion of the offer and sale of the
                                            Securities an event occurs that would cause the Registration Statement or Prospectus (as
                                            supplemented or amended) to contain an untrue statement of a material fact or to omit to
                                            state a material fact necessary in order to make the statements therein, in light of the
                                            circumstances under which they were made, not misleading, the Company will notify Spartan
                                            immediately of such event and Spartan will suspend solicitations of the prospective purchasers
                                            of the Securities until such time as the Company shall prepare a supplement or amendment
                                            to the Registration Statement or Prospectus that corrects such statement or omission.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Lock-Ups</U></B>.
                                            In connection with the Placement, the Company&rsquo;s directors, executive officers, employees
                                            and shareholders holding at least ten percent (10%) of the outstanding common stock will
                                            enter into customary &ldquo;lock-up&rdquo; agreements in favor of the Placement Agent for
                                            a period of sixty (60) days after the Closing of the Placement (the &ldquo;<B><U>Lock-Up
                                            Period</U></B>&rdquo;); provided, however, that any sales by parties to the lock-ups shall
                                            be subject to the lock-up agreements and provided further, that none of such common stock
                                            shall be saleable in the public market until the expiration of the Lock-Up Period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Expenses</U></B>.
                                            Out of the proceeds of the Closing, the Company shall pay Spartan up to $40,000 for fees
                                            and expenses of legal counsel and other expenses, including but not limited to, roadshow
                                            expenses and cost of background checks; plus the additional amount payable by the Company
                                            pursuant to the following sentence and, if applicable, the costs associated with the use
                                            of a third-party electronic road show service (such as Net Roadshow); provided, however,
                                            that such amount in no way limits or impairs the indemnification and contribution provisions
                                            of this Agreement. The Company will bear all fees, disbursements and expenses in connection
                                            with the Placement, including, without limitation, the Company&rsquo;s legal and accounting
                                            fees and disbursements; the costs of preparing, printing, mailing and delivering the Registration
                                            Statement, the preliminary and final prospectus contained therein and amendments thereto,
                                            post-effective amendments and supplements thereto, any other offering materials, this Agreement
                                            and related documents (all in such quantities as Spartan may reasonably require); preparing
                                            and printing stock certificates and warrant certificates; the costs of any &ldquo;due diligence&rdquo;
                                            meetings or background checks for members of management; filing fees (including SEC filing
                                            fees), costs and expenses (including third party expenses and disbursements) incurred in
                                            registering the Placement, FINRA filing fees; costs and expenses of qualifying the offering
                                            under the &ldquo;blue sky&rdquo; laws of the states specified by Spartan; preparation of
                                            leather bound volumes and Lucite cube mementos in such quantities as Spartan may reasonably
                                            request in connection with an underwritten offering; transfer taxes; and transfer and warrant
                                            agent and registrar fees, but excluding those costs and expenses that FINRA regulations require
                                            to be borne by a selling agent, placement agent or underwriter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Closing;
                                            Closing Deliverables</U></B>. Unless otherwise directed by the Placement Agent, settlement
                                            of the Securities shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<B><U>DVP</U></B>&rdquo;)
                                            (i.e., on the Closing Date, the Company shall cause the Depositary to issue the Securities
                                            directly to the clearing firm designated by the Placement Agent; upon receipt of such Securities,
                                            the Placement Agent shall promptly electronically deliver such Securities to the applicable
                                            Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm)
                                            by wire transfer to the Company).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1. <B><U>Company
Deliveries</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.1. On
the date hereof, the Company shall deliver each of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.1.1 This
Agreement duly executed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.1.2 A
certificate executed by the Chief Financial Officer of the Company in customary form reasonably satisfactory to the Placement Agent and
its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.1.3 The
Lock-Up Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.2. On
or prior to the Closing Date, the Company shall deliver each the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.2.1 A
legal opinion of TroyGould PC, addressed to the Placement Agent and the Purchasers, in form and substance reasonably acceptable to the
Placement Agent and Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.2.2 A
negative assurance letter from TroyGould PC, addressed to the Placement Agent and dated the Closing Date, in a form reasonably satisfactory
to the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.2.3 A
copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, a certificate
(or at the request of the Purchaser, book entry statement) evidencing a number of Shares equal to such Purchaser&rsquo;s Subscription
Amount, registered in the name of such Purchaser; subject to the first sentence of Section 7, a copy of the irrevocable instructions
to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal
at Custodian system (&ldquo;<B>DWAC</B>&rdquo;) Shares equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable
to Shares, divided by the Per Unit Purchase Price, registered in the name of such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.2.4 For
each Purchaser of Pre-Funded Warrants pursuant to Section <I> </I>7, a Pre-Funded Warrant registered in the name of such Purchaser
to purchase up to a number of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to
Pre-Funded Warrants divided by the Per Share Purchase Price, with an exercise price equal to $0.00001, subject to adjustment as provided
therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.2.5 Subject
to the provisions of Section 7.1 regarding settlement via DVP, the Company&rsquo;s wire instructions, on Company letterhead and executed
by the Chief Executive Officer or Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.2.6 A
duly executed and delivered Officers&rsquo; Certificate, in customary form reasonably satisfactory to the Placement Agent and its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.2.7 A
cold comfort letter from the Company&rsquo;s auditor, addressed to the Placement Agent in form and substance reasonably satisfactory
in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.2.8 The
Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Representations
                                            and Warranties of the Company</U></B>. The representations and warranties of the Company
                                            contained herein shall be true and correct on the date hereof and on and as of the Closing
                                            Date, as the case may be, and the statements of the Company and its officers made in any
                                            certificates delivered pursuant to this Agreement shall be true and correct on and as of
                                            the Closing Date, as the case may be.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.1. <B><U>Subsidiaries</U></B>.
All of the direct and indirect subsidiaries of the Company are set forth on Exhibit 21.1 to the Company&rsquo;s Annual Report on Form
10-K. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear
of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid,
non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries,
all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.2. <B><U>Organization
and Qualification</U></B>. Each of the Company and its operating Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could
not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<B><U>Material
Adverse Effect</U></B>&rdquo;; provided, however, that &ldquo;<B><U>Material Adverse Effect</U></B>&rdquo; shall not include any event,
occurrence, fact, condition or change, directly or indirectly, arising out of or attributable to: (i) the announcement, pendency or completion
of the transactions contemplated by the Transaction Documents or (ii) any action required or permitted by the Transaction Documents or
any action taken (or omitted to be taken) with the written consent of or at the written request of Purchaser). As to all Company and
Subsidiary power, authority and qualification, no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing
or seeking to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.3. <B><U>Authorization;
Enforcement</U></B>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other
than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or
upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.4. <B><U>No
Conflicts</U></B>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which
it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.5. <B><U>Filings,
Consents and Approvals</U></B>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person
in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required
pursuant to this Agreement, (ii) the filing with the Commission of the Prospectus Supplement to the Shelf Registration Statement, (iii)
the notice and/or application(s) to each applicable Trading Market for the issuance and sale of the Securities and the listing of the
Shares and Warrant Shares for trading thereon in the time and manner required thereby, (iv) the filing of Form D with the Commission
and such other filings as are required to be made under applicable state securities laws (the &ldquo;<B><U>Required Approvals</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1. <B><U>Issuance
of the Securities; Registration</U></B>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable (which means that no further sums are required to
be paid by the holders thereof in connection with the issue thereof), free and clear of all Liens imposed by the Company other than restrictions
on transfer provided for in the Transaction Documents and applicable law. The Warrant Shares, when issued in accordance with the terms
of the Transaction Documents, will be validly issued, fully paid and nonassessable (which means that no further sums are required to
be paid by the holders thereof in connection with the issue thereof), free and clear of all Liens imposed by the Company other than restrictions
on transfer provided for in the Transaction Documents and applicable law. As of the date hereof, the Company has reserved and the Company
shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for
the purpose of enabling the Company to issue Shares pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.1. <B><U>Registration
Statement</U></B>. The Company has prepared and filed the Shelf Registration Statement in conformity with the requirements of the Securities
Act, which became effective on , including the Prospectus, and such amendments and supplements thereto as may have been required to the
date of this Agreement. The Shelf Registration Statement is effective under the Securities Act and no stop order preventing or suspending
the effectiveness of the Shelf Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission
and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company,
if required by the rules and regulations of the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule
424(b). At the time the Shelf Registration Statement and any amendments thereto became effective, at the date of this Agreement and at
the Closing Date, the Shelf Registration Statement and any amendments thereto conformed and will conform in all material respects to
the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments
or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed
and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. The Company was at the time of the filing of the Shelf Registration Statement eligible to
use Form S-1. The Company is eligible to use Form S-3 under the Securities Act and it meets the requirements with respect to the aggregate
market value of securities being sold pursuant to this offering and during the twelve (12) months prior to this offering, as set forth
in General Instruction I.B.1. of Form S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.2. <B><U>Capitalization</U></B>.
The capitalization of the Company as of the date hereof is as set forth on Schedule  8.1.2, which Schedule  8.1.2 shall also include
the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof. Other than
as stated in Schedule  8.1.2, the Company has not issued any capital stock since its most recently filed periodic report under the Exchange
Act, other than pursuant to the exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares
of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise
of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated
by the Transaction Documents. Except as set forth in Schedule  0, or pursuant to this Agreement, there are no outstanding options,
warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations
convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common
Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary
is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The
issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities
to any Person (other than the Purchasers). Except as set forth in Schedule  8.1.2, there are no outstanding securities or instruments
of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or
instrument upon an issuance of securities by the Company or any Subsidiary. Except as set forth in Schedule  8.1.2, there are no outstanding
securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the
Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements
or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued,
fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding
shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval
or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There
are no stockholders&rsquo; agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock
to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.3. <B><U>SEC
Reports; Financial Statements</U></B>. The Company has filed all reports, schedules, forms, statements and other documents required to
be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein together with the Prospectus and
the Prospectus Supplement being collectively referred to herein as the &ldquo;<B><U>SEC Reports</U></B>&rdquo;) on a timely basis or
has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension.
As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange
Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial
statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the
rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been
prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved
(&ldquo;<B><U>GAAP</U></B>&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto, and fairly
present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof
and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial,
year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.4. <B><U>Material
Changes; Undisclosed Events, Liabilities or Developments</U></B>. Since the date of the latest audited financial statements included
within the SEC Reports, except as set forth on Schedule  8.1.4, (i) there has been no event, occurrence or development that has had or
that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence
or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or
their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed
at least one (1) Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.5. <B><U>Litigation</U></B>.
Except as set forth in Schedule  8.1.5, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or,
to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before
or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<B><U>Action</U></B>&rdquo;). None of the Actions set forth on Schedule  8.1.5, (i) adversely affects or challenges
the legality, validity or enforceability of any of the Transaction Documents or (ii) would, if there were an unfavorable decision, have
or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer
thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws
or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the Commission involving the Company or any current or former director or officer of the Company, except in the
ordinary course of business that would not have a Material Adverse Effect. The Commission has not issued any stop order or other order
suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.6. <B><U>Labor
Relations</U></B>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the
Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.7. <B><U>Compliance</U></B>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii) is in violation of any judgment, decree, or order of any court, arbitrator or other governmental
authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including
without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety,
product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result
in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.8. <B><U>Environmental
Laws</U></B>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &ldquo;<B><U>Hazardous Materials</U></B>&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<B><U>Environmental Laws</U></B>&rdquo;);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.9. <B><U>Regulatory
Permits</U></B>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<B><U>Material
Permits</U></B>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation
or modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.10. <B><U>Title
to Assets</U></B>. The Company and the Subsidiaries have good and marketable title in fee simple to, or have valid and marketable rights
to lease or otherwise use, all real property and all personal property that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens that do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made in accordance with GAAP, and the payment of which is
neither delinquent nor subject to penalties. Neither the Company nor any of its Subsidiaries has received any written notice of any claim
of any sort that has been asserted by anyone adverse to the rights of the Company or its Subsidiaries under any of the leases or subleases
or licenses or with respect to the properties mentioned above, or affecting or questioning the rights of the Company or any Subsidiary
to the continued possession or use of the leased or subleased or licensed premises or the properties mentioned above, other than such
claims which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.11. <B><U>Intellectual
Property</U></B>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark
applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and
similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<B><U>Intellectual Property Rights</U></B>&rdquo;).
None of, and neither the Company nor any Subsidiary has received notice (written or otherwise) that any of, the Intellectual Property
Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years after the
date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements
included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate
or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect.
To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another
Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect
the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.12. <B><U>Insurance</U></B>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not
limited to, directors and officers insurance coverage in amount deemed prudent by the Company. Neither the Company nor any Subsidiary
has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.13. <B><U>Transactions
with Affiliates and Employees</U></B>. Except as set forth on Schedule  8.1.13, during the past three fiscal years and the subsequent
interim period through the date of this Agreement, none of the officers or directors of the Company or any Subsidiary and, to the knowledge
of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any
Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing
for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of
money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge
of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director,
trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for
services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock
option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.14. <B><U>Sarbanes-Oxley;
Internal Accounting Controls</U></B>. The Company and the Subsidiaries are in material compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. Except as set forth on
Schedule  8.1.14, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable
assurance that: (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information
required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized
and reported, within the time periods specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have
evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period
covered by the most recently filed periodic report under the Exchange Act (such date, the &ldquo;<B><U>Evaluation Date</U></B>&rdquo;).
The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about
the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation
Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the
Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial
reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.15. <B><U>Certain
Fees</U></B>. Except for the fees and expenses of the Placement Agent, no brokerage or finder&rsquo;s fees or commissions are or will
be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this
Section  8.1.15 that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.16. <B><U>Investment
Company</U></B>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not
be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.17. <B><U>Registration
Rights</U></B>. Except as disclosed on Schedule  8.1.18, no Person has any right to cause the Company or any Subsidiary to effect the
registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.18. <B><U>Listing
and Maintenance Requirements</U></B>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the
Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the
Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such
registration. Except as disclosed on Schedule  8.1.19 and in the Company&rsquo;s securities filings, including the current S-1 Registration
Statement, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common
Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements
of such Trading Market. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another
established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established
clearing corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.19. <B><U>Application
of Takeover Protections</U></B>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their
obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s
issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.20. <B><U>Disclosure</U></B>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information
that it believes constitutes or might constitute material, non-public information. The Company understands and confirms that the Purchasers
will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by
or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions
contemplated hereby, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading.
The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order
to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company
acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in THE Securities Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.21. <B><U>No
Integrated Offering</U></B>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties, neither the Company, nor
any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with
prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of any such securities under
the Securities Act, or (ii) any applicable stockholder approval provisions of any Trading Market on which any of the securities of the
Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.22. <B><U>Solvency</U></B>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds the amount
that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known contingent
liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its business as
now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of
the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the
current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year after the Closing Date. Schedule  8.1.23 sets forth as of the date hereof all outstanding secured
and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes
of this Agreement, &ldquo;<B><U>Indebtedness</U></B>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess of
$50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent
obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated
balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar
transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases
required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.23. <B><U>Tax
Status</U></B>. Except as disclosed in Schedule  8.1.24, the Company and its Subsidiaries each (i) has made or filed all material United
States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction
to which it is subject, (ii) has paid all material taxes and other governmental assessments and charges that are material in amount,
shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate
for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There
are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company
or of any Subsidiary know of no basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.24. <B><U>No
General Solicitation</U></B>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and
certain other &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.25. <B><U>Foreign
Corrupt Practices Act</U></B>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent
or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds,
(iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of
which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.26. <B><U>Accountants</U></B>.
The Company&rsquo;s accounting firm is Weinberg &amp; Company, P.A., with offices at 1925 Century Park East,, Suite 1120, Los Angeles,
CA 90067. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by
the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company&rsquo;s Annual
Report for the now current fiscal year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.27. <B><U>No
Disagreements with Accountants and Lawyers</U></B>. There are no disagreements of any kind presently existing, or reasonably anticipated
by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company and the Company
is current with respect to any fees owed to its accountants and lawyers which could affect the Company&rsquo;s ability to perform any
of its obligations under any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.28. <B><U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U></B>. The Company acknowledges and agrees that each of the Purchasers is acting
solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.29. <B><U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U></B>. Notwithstanding anything in this Agreement or elsewhere herein to the contrary,
it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any
Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities
based on securities issued by the Company or to hold the Securities for any specified term, (ii) past or future open market or other
transactions by any Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before
or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&rsquo;s
publicly-traded securities, (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser
is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock and (iv) each Purchaser shall
not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction.
The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during
the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Warrant Shares
deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing
stockholders&rsquo; equity interests in the Company at and after the time that the hedging activities are being conducted. The Company
acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.30. <B><U>Regulation
M Compliance</U></B>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any
action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&rsquo;s placement agent in connection
with the placement of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.31. <B><U>Officers&rsquo;
Certificate</U></B>. Any certificate signed by any duly authorized officer of the Company and delivered to the Purchasers shall be deemed
a representation and warranty by the Company to the Purchasers as to the matters covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.32. <B><U>D&amp;O
Questionnaires</U></B>. To the Company&rsquo;s knowledge, all information contained in the questionnaires most recently completed by
each of the Company&rsquo;s directors and officers and beneficial owner of 5% or more of the shares of Common Stock or Common Stock Equivalents
is true and correct in all respects and the Company has not become aware of any information which would cause the information disclosed
in such questionnaires become inaccurate and incorrect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.33. <B><U>Stock
Option Plans</U></B>. Each stock option granted by the Company under the Company&rsquo;s stock option plan, if any, was granted (i) in
accordance with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market
value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted
under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no
Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with,
the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results
or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.34. <B><U>Office
of Foreign Assets Control</U></B>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer,
agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (&ldquo;<B><U>OFAC</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.35. <B><U>U.S.
Real Property Holding Corporation</U></B>. The Company is not and has never been a U.S. real property holding corporation within the
meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.36. <B><U>Bank
Holding Company Act</U></B>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act
of 1956, as amended (the &ldquo;<B><U>BHCA</U></B>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System
(the &ldquo;<B><U>Federal Reserve</U></B>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly
or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or
more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company
nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that
is subject to the BHCA and to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.37. <B><U>Money
Laundering</U></B>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<B><U>Money Laundering Laws</U></B>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.38. <B><U>Other
Covered Persons</U></B>. Other than the Placement Agent, the Company is not aware of any person that has been or will be paid (directly
or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.39. <B><U>FDA</U></B>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<B><U>FDA</U></B>&rdquo;) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<B><U>FDCA</U></B>&rdquo;) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<B><U>Pharmaceutical
Product</U></B>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter
or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and
promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company
or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of
its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries,
and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of
the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations
of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United
States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving
or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.40. <B><U>Cybersecurity</U></B>.
(i) (a) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s
information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees,
suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;<B><U>IT
Systems and Data</U></B>&rdquo;) and (b) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event
or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii)
the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and
regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating
to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification, except, in the case of clauses (i) and (ii) herein, as would not, individually or in the aggregate, have a Material
Adverse Effect; (iii) the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain
and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems
and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry
standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Conditions
                                            of the Obligations of the Placement Agent</U></B>. The obligations of the Placement Agent
                                            hereunder shall be subject to the accuracy of the representations and warranties on the part
                                            of the Company set forth in Section  8 hereof, in each case as of the date hereof and
                                            as of the Closing Date as though then made, to the timely performance by each of the Company
                                            of its covenants and other obligations hereunder on and as of such dates, and to each of
                                            the following additional conditions:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1. <B><U>Regulatory
Matters</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.1. <B><U>Effectiveness
of Registration Statement; Rule 424 Information</U></B>. The Registration Statement is effective on the date of this Agreement, and,
on the Closing Date no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto
has been issued under the Securities Act, no order preventing or suspending the use of any Preliminary Prospectus or the Prospectus has
been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&rsquo;s knowledge, contemplated
by the Commission. The Company has complied with each request (if any) from the Commission for additional information. All filings with
the Commission required by Rule 424 under the Securities Act to have been filed by the Closing Date shall have been made within the applicable
time period prescribed for such filing by Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.2. <B><U>Listing
of Additional Shares</U></B>. On or before the Closing Date, the Company shall have filed a notice with the Exchange with respect to
the Company&rsquo;s additional listing of the securities sold in the Placement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2. <B><U>Closing
Deliverables</U></B>. The Company shall have delivered all closing deliverables to the Placement Agent as set forth in Section  7.1
as of the time required and in form reasonably satisfactory to the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.1. <B><U>No
Material Changes</U></B>. Prior to and on the Closing Date: (i) there shall have been no Material Adverse Effect or development involving
a prospective Material Adverse Effect in the condition or prospects or the business activities, financial or otherwise, of the Company
from the latest dates as of which such condition is set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus;
(ii) no action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company or any affiliates
of the Company before or by any court or federal or state commission, board or other administrative agency wherein an unfavorable decision,
ruling or finding may materially adversely affect the business, operations, prospects or financial condition or income of the Company,
except as set forth in the Registration Statement and the Prospectus; (iii) no stop order shall have been issued under the Securities
Act and no proceedings therefor shall have been initiated or threatened by the Commission; and (iv) the Registration Statement and the
Prospectus and any amendments or supplements thereto shall contain all material statements which are required to be stated therein in
accordance with the Securities Act and the Securities Act Regulations and shall conform in all material respects to the requirements
of the Securities Act and the Securities Act Regulations, and neither the Registration Statement nor the Prospectus nor any amendment
or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.2. <B><U>Additional
Documents</U></B>. At the Closing Date, Placement Agent&rsquo;s counsel shall have been furnished with such documents and opinions as
they may require in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions,
herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated
shall be satisfactory in form and substance to the Placement Agent and Placement Agent&rsquo;s counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Definitions</U></B>.
                                            In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement,
                                            the following terms have the meanings:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1. &ldquo;<B><U>Affiliate</U></B>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2. &ldquo;<B><U>Board
of Directors</U></B>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3. &ldquo;<B><U>Business
Day</U></B>&rdquo; means a Calendar Day other than a Saturday, Sunday or any other Calendar Day which is a federal legal holiday in the
United States or any Calendar Day on which the commercial banks in the City of New York are required by law or other governmental action
to close, provided that the commercial banks in the City of New York shall not be deemed to be required to be closed due to a &ldquo;stay
at home,&rdquo; &ldquo;shelter in place,&rdquo; &ldquo;non-essential employee&rdquo; or similar orders or restrictions or the closure
of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including
for wire transfers) of commercial banks in the City of New York generally are open for use by customers on such Calendar Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4. &ldquo;<B><U>Calendar
Day</U></B>&rdquo; means each and every day of the week (Sunday, Monday, Tuesday, Wednesday, Thursday, Friday and Saturday).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5. &ldquo;<B><U>Closing
Date</U></B>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second (2nd) Trading
Day following the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6. &ldquo;<B><U>Common
Stock</U></B>&rdquo; means the common stock of the Company, $0.0001 par value per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7. &ldquo;<B><U>Common
Stock Equivalents</U></B>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8. &ldquo;<B><U>Disclosure
Schedules</U></B>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9. &ldquo;&ldquo;<B><U>Exchange
Act</U></B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10. &ldquo;<B><U>Liens</U></B>&rdquo;
means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11. &ldquo;<B><U>Person</U></B>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12. &ldquo;<B><U>Placement
Agent</U></B>&rdquo; means Spartan Capital Securities, LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13. &ldquo;<B><U>Placement
Agent Counsel</U></B>&rdquo; means Kaufman &amp; Canoles, P.C., with office at Two James Center, 14th Floor, 1021 E. Cary St., Richmond,
VA 23219.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14. &ldquo;<B><U>Pre-Funded
Warrants</U></B>&rdquo; means the pre-funded Common Stock purchase warrants delivered to the Purchasers at the Closing, which Pre-Funded
Warrants shall be exercisable immediately and shall expire when exercised in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15. &ldquo;<B><U>Proceeding</U></B>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16. &ldquo;<B><U>Purchaser</U></B>&rdquo;
means each purchaser of Securities in the Placement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17. &ldquo;<B><U>Shares</U></B>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement, but excluding the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18. &ldquo;<B><U>Subscription
Amount</U></B>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder in United
States dollars and in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19. &ldquo;<B><U>Subsidiary</U></B>&rdquo;
means any subsidiary of the Company as set forth in the SEC Reports and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20. &ldquo;<B><U>Testing-the-Waters
Communication</U></B>&rdquo; means any oral or Written Communication with potential investors undertaken in reliance on Section 5(d)
of the Securities Act and Rule 163B thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21. &ldquo;<B><U>Trading
Day</U></B>&rdquo; means a Calendar Day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22. &ldquo;<B><U>Trading
Market</U></B>&rdquo; means any of the following markets or exchanges on which the Common Shares are listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New
York Stock Exchange, the OTCQB, OTCQX, Pink Open Market (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23. &ldquo;<B><U>Transaction
Documents</U></B>&rdquo; means this Agreement, the Securities, the Securities Purchase Agreement, the Lock-Up Agreement and all exhibits
and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24. &ldquo;<B><U>Transfer
Agent</U></B>&rdquo; means Computershare Trust Company, N.A., the current transfer agent of the Company, with a mailing address of 150
Royall Street, Suite 101 Canton, MA 02021 and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25. &ldquo;<B><U>Warrants</U></B>&rdquo;
means, collectively, the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26. &ldquo;<B><U>Warrant
Shares</U></B>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27. &ldquo;<B><U>Written
Communication</U></B>&rdquo; has the meaning set forth in Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Termination</U></B>.
                                            Notwithstanding anything to the contrary contained herein, the Company agrees that the provisions
                                            relating to the payment of fees, reimbursement of expenses, right of first refusal, tail
                                            fee, indemnification and contribution, equitable remedies, confidentiality, conflicts, independent
                                            contractor and waiver of the right to trial by jury will survive any termination or expiration
                                            of this Agreement. Notwithstanding anything to the contrary contained herein, the Company
                                            has the right to terminate the placement agent agreement for cause in compliance with FINRA
                                            Rule 5110(g)(5)(B)(i). The exercise of such right of termination for cause eliminates the
                                            Company&rsquo;s obligations with respect to the provisions relating to the tail fees and
                                            right of first refusal. Notwithstanding anything to the contrary contained in this Agreement,
                                            in the event that no Placement is completed for any reason whatsoever during the Engagement
                                            Period, the Company shall be obligated to pay to Spartan its actual and accountable out-of-pocket
                                            expenses related to the Placement (including the fees and disbursements of Placement Agent&rsquo;s
                                            Counsel) and if applicable, for electronic road show service used in connection with the
                                            Placement. During the engagement hereunder: (i) the Company will not, and will not permit
                                            its representatives to, other than in coordination with Spartan, contact or solicit institutions,
                                            corporations or other entities or individuals as potential purchasers of the Securities and
                                            (ii) the Company will not pursue any financing transaction which would be in lieu of the
                                            Placement. Furthermore, the Company agrees that during Spartan&rsquo;s engagement hereunder,
                                            all inquiries from prospective investors will be referred to Spartan. Regardless of termination
                                            and except as stated in this Section  11, Section <B>Error! Reference source not found.</B>
                                            of this Agreement will still remain in full effect if an offering is consummated.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Publicity</U></B>.
                                            The Company agrees that it will not issue press releases or engage in any other publicity,
                                            without Spartan&rsquo;s prior written consent, commencing on the date hereof and continuing
                                            until the final Closing of the Placement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Information</U></B>.
                                            During the Engagement Period or until the Closing, the Company agrees to cooperate with Spartan
                                            and to furnish, or cause to be furnished, to Spartan, any and all information and data concerning
                                            the Company, and the Placement that Spartan deems appropriate (the &ldquo;<B><U>Information</U></B>&rdquo;).
                                            The Company will provide Spartan reasonable access during normal business hours from and
                                            after the date of execution of this Agreement until the Closing to all of the Company&rsquo;s
                                            assets, properties, books, contracts, commitments and records and to the Company&rsquo;s
                                            officers, directors, employees, appraisers, independent accountants, legal counsel and other
                                            consultants and advisors. Except as contemplated by the terms hereof or as required by applicable
                                            law, Spartan will keep strictly confidential all non-public Information concerning the Company
                                            provided to Spartan. No obligation of confidentiality will apply to Information that: (a)
                                            is in the public domain as of the date hereof or hereafter enters the public domain without
                                            a breach by Spartan, (b) was known or became known by Spartan prior to the Company&rsquo;s
                                            disclosure thereof to Spartan as demonstrated by the existence of its written records, (c)
                                            becomes known to Spartan from a source other than the Company which information is not provided
                                            by the breach of an obligation of confidentiality owed to the Company, (d) is disclosed by
                                            the Company to a third party without restrictions on its disclosure or (e) is independently
                                            developed by Spartan as demonstrated by its written records. For the avoidance of doubt,
                                            except as otherwise provided herein, all information which is not publicly available relating
                                            to the Company&rsquo;s proprietary technology is proprietary and confidential.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>No
                                            Third Party Beneficiaries; No Fiduciary Obligations</U></B>. This Agreement does not create,
                                            and shall not be construed as creating, rights enforceable by any person or entity not a
                                            party hereto, except those entitled hereto by virtue of the indemnification provisions hereof.
                                            The Company acknowledges and agrees that: (i) Spartan is not and shall not be construed as
                                            a fiduciary of the Company and shall have no duties or liabilities to the equity holders
                                            or the creditors of the Company or any other person or entity by virtue of this Agreement
                                            or the retention of Spartan hereunder, all of which are hereby expressly waived; and (ii)
                                            Spartan is a full service securities firm engaged in a wide range of businesses and from
                                            time to time, in the ordinary course of its business, Spartan or its affiliates may hold
                                            long or short positions and trade or otherwise effect transactions for its own account or
                                            the account of its customers in debt or equity securities or loans of the companies which
                                            may be the subject of the transactions contemplated by this Agreement. During the course
                                            of Spartan&rsquo;s engagement with the Company, Spartan may have in its possession material,
                                            non-public information regarding other companies that could potentially be relevant to the
                                            Company or the transactions contemplated herein but which cannot be shared due to an obligation
                                            of confidence to such other companies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Indemnification,
                                            Advancement &amp; Contribution</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1. The
Company hereby agrees to indemnify and hold harmless Spartan and its affiliates, and the respective controlling persons, directors, officers,
managers, members, shareholders, agents and employees of any of the foregoing (collectively the &ldquo;<B><U>Indemnified Persons</U></B>&rdquo;),
from and against any and all claims, actions, suits, proceedings (including those of shareholders), damages, liabilities and expenses
incurred by any of them (including the reasonable fees and expenses of counsel), as incurred, whether or not the Company is a party thereto
(collectively a &ldquo;<B><U>Claim</U></B>&rdquo;), that are (A) related to or arise out of (i) any actions taken or omitted to be taken
(including any untrue statements made or any statements omitted to be made) by the Company, or (ii) any actions taken or omitted to be
taken by any Indemnified Person in connection with the Company&rsquo;s engagement of Spartan, or (B) otherwise relate to or arise out
of Spartan&rsquo;s activities on the Company&rsquo;s behalf under Spartan&rsquo;s engagement, and the Company shall reimburse any Indemnified
Person for all expenses (including the reasonable fees and expenses of counsel) and shall advance payment for such expenses as incurred
by such Indemnified Person in connection with investigating, preparing or defending any such claim, action, suit or proceeding, whether
or not in connection with pending or threatened litigation in which any Indemnified Person is a party. The Company will not, however,
be responsible for any Claim that is finally judicially determined to have resulted from the gross negligence or willful misconduct of
any such Indemnified Person for such Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2. The
Company further agrees that it will not, without the prior written consent of Spartan, settle, compromise or consent to the entry of
any judgment in any pending or threatened Claim in respect of which indemnification may be sought hereunder (whether or not any Indemnified
Person is an actual or potential party to such Claim), unless such settlement, compromise or consent includes an unconditional, irrevocable
release of each Indemnified Person from any and all liability arising out of such Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3. Promptly
upon receipt by an Indemnified Person of notice of any complaint or the assertion or institution of any Claim with respect to which indemnification
is being sought hereunder, such Indemnified Person shall notify the Company in writing of such complaint or of such assertion or institution
but failure to so notify the Company shall not relieve the Company from any obligation it may have hereunder, except and only to the
extent such failure results in the forfeiture by the Company of substantial rights and defenses. If the Company so elects, or is requested
by such Indemnified Person, the Company will assume the defense of such Claim, including the employment of counsel for such Indemnified
Person and the payment of the fees and expenses of such counsel, provided, however, that such counsel shall be reasonably satisfactory
to the Indemnified Person and provided further that if the legal counsel to such Indemnified Person reasonably determines that having
common counsel would present such counsel with a conflict of interest or if the defendant in, or target of, any such Claim, includes
an Indemnified Person and the Company, and legal counsel to such Indemnified Person reasonably concludes that there may be legal defenses
available to it or other Indemnified Persons different from or in addition to those available to the Company, such Indemnified Person
will employ its own separate counsel (limited to one law firm and local counsel, if necessary) to represent or defend him, her or it
in any such Claim and the Company shall pay the reasonable fees and expenses of such counsel. If the Company does not assume the defense
of such Claim, such Indemnified Person will employ its own separate counsel (limited to one law firm and local counsel, if necessary)
to represent or defend him, her, or it in any such Claim and the Company shall pay the reasonable fees and expenses of such counsel.
Notwithstanding anything herein to the contrary, if the Company fails timely or diligently to defend, contest, or otherwise protect against
any Claim, the relevant Indemnified Person shall have the right, but not the obligation, to defend, contest, compromise, settle, assert
crossclaims, or counterclaims or otherwise protect against the same, and shall be fully indemnified by the Company therefor, including
without limitation, for the reasonable fees and expenses of its counsel (limited to one law firm and local counsel, if necessary) and
all amounts paid as a result of such Claim or the compromise or settlement thereof. In addition, with respect to any Claim in which the
Company assumes the defense, the Indemnified Person shall have the right to participate in such Claim and to retain his, her or its own
counsel therefor at his, her or its own expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.4. The
Company agrees that if any indemnity sought by an Indemnified Person hereunder is held by a court to be unavailable for any reason then
(whether or not Spartan is the Indemnified Person), the Company and Spartan shall contribute to the Claim for which such indemnity is
held unavailable in such proportion as is appropriate to reflect the relative benefits to the Company, on the one hand, and Spartan on
the other, in connection with Spartan&rsquo;s engagement referred to above, subject to the limitation that in no event shall the amount
of Spartan&rsquo;s contribution to such Claim exceed the amount of fees actually received by Spartan from the Company pursuant to Spartan&rsquo;s
engagement. The Company hereby agrees that the relative benefits to the Company, on the one hand, and Spartan on the other, with respect
to Spartan&rsquo;s engagement shall be deemed to be in the same proportion as (a) the total value paid or proposed to be paid or received
by the Company pursuant to the Placement (whether or not consummated) for which Spartan is engaged to render services bears to (b) the
fee paid or proposed to be paid to Spartan in connection with such engagement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.5. The
Company&rsquo;s indemnity, reimbursement and contribution obligations under this Agreement (a) shall be in addition to and shall in no
way limit or otherwise adversely affect any rights that any Indemnified Person may have at law or at equity and (b) shall be effective
whether or not the Company is at fault in any way.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.6. Spartan
and the Company further agree that neither Spartan nor any of its affiliates or any of its or their respective officers, directors, controlling
persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), employees or agents shall have any
liability to the Company, its security holders or creditors, or any person asserting claims on behalf of or in the right of the Company
(whether direct or indirect, in contract, tort, for an act of negligence or otherwise) for any losses, fees, damages, liabilities, costs,
expenses or equitable relief arising out of or relating to this Agreement or the services rendered hereunder, except for losses, fees,
damages, liabilities, costs or expenses that arise out of or are based on any action of or failure to act by Spartan and that are finally
judicially determined to have resulted solely from the gross negligence or willful misconduct of Spartan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Governing
                                            Law; Jurisdiction and Venue Arbitration</U></B>. This Agreement will be governed by and construed
                                            in accordance with the laws of the State of Delaware, without regard to principles of conflicts
                                            of law. Any controversy between the parties to this Agreement, or arising out of the Agreement,
                                            shall be resolved by arbitration before the American Arbitration Association (&ldquo;<B><U>AAA</U></B>&rdquo;)
                                            in New York, New York. The following arbitration agreement should be read in conjunction
                                            with these disclosures:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1. ARBITRATION
IS FINAL AND BINDING ON THE PARTIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.2. THE
PARTIES ARE WAIVING THEIR RIGHT TO SEEK REMEDIES IN COURT, INCLUDING THE RIGHT TO JURY TRIAL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.3. PRE-ARBITRATION
DISCOVERY IS GENERALLY MORE LIMITED THAN AND DIFFERENT FROM COURT PROCEEDING; AND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.4. THE
ARBITRATORS&rsquo; AWARD IS NOT REQUIRED TO INCLUDE FACTUAL FINDING OR LEGAL REASONING AND ANY PARTY&rsquo;S RIGHT TO APPEAL OR TO SEEK
MODIFICATION OF RULINGS BY THE ARBITRATORS IS STRICTLY LIMITED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.5. <U>ARBITRATION
AGREEMENT</U>. ANY AND ALL CONTROVERSIES, DISPUTES OR CLAIMS BETWEEN SPARTAN AND YOU OR YOUR AGENTS, REPRESENTATIVES, EMPLOYEES, DIRECTORS,
OFFICERS OR CONTROL PERSONS, ARISING OUT OF, IN CONNECTION WITH, OR WITH RESPECT TO (i) ANY PROVISIONS OF OR THE VALIDITY OF THIS AGREEMENT
OR ANY RELATED AGREEMENTS, (ii) THE RELATIONSHIP OF THE PARTIES HERETO, OR (iii) ANY CONTROVERSY ARISING OUT OF YOUR BUSINESS SHALL BE
CONDUCTED BY THE AMERICAN ARBITRATION ASSOCIATION UNDER ITS COMMERCIAL ARBITRATION RULES. ARBITRATION MUST BE COMMENCED BY SERVICE OF
A WRITTEN DEMAND FOR ARBITRATION OR A WRITTEN NOTICE OF INTENTION TO ARBITRATE. IF YOU ARE A PARTY TO SUCH ARBITRATION, TO THE EXTENT
PERMITTED BY THE RULES OF THE APPLICABLE ARBITRATION TRIBUNAL, THE ARBITRATION SHALL BE CONDUCTED IN NEW YORK, NEW YORK. THE DECISION
AND AWARD OF THE ARBITRATORS(S) SHALL BE CONCLUSIVE AND BINDING UPON ALL PARTIES, AND ANY JUDGMENT UPON ANY AWARD RENDERED MAY BE ENTERED
IN THE STATE OR FEDERAL COURTS LOCATED IN NEW YORK, NEW YORK, OR ANY OTHER COURT HAVING JURISDICTION THEREOF, AND NEITHER PARTY SHALL
OPPOSE SUCH ENTRY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Miscellaneous</U></B>.
                                            The Company represents and warrants that it has all required power and authority to enter
                                            into and carry out the terms and provisions of this Agreement and the execution, delivery
                                            and performance of this Agreement does not breach or conflict with any agreement, document
                                            or instrument to which it is a party or bound. The binding provisions of this Agreement are
                                            legally binding upon and inure to the benefit of both the Company and Spartan and their respective
                                            assigns, successors, and legal representatives. If any provision of this Agreement is determined
                                            to be invalid or unenforceable in any respect, such determination will not affect such provision
                                            in any other respect, and the remainder of the placement agent agreement shall remain in
                                            full force and effect. This Agreement may be executed in counterparts (including electronic
                                            counterparts), each of which shall be deemed an original but all of which together shall
                                            constitute one and the same instrument. The undersigned hereby consents to receipt of this
                                            Agreement in electronic form and understands and agrees that this Agreement may be signed
                                            electronically. Signatures to this Agreement transmitted in electronic form will have the
                                            same effect as physical delivery of a paper document bearing the original signature, and
                                            if any signature is delivered electronically evidencing an intent to sign this Agreement,
                                            such electronic mail or other electronic transmission shall create a valid and binding obligation
                                            of the undersigned with the same force and effect as if such signature were an original.
                                            Execution and delivery of this Agreement by electronic mail or other electronic transmission
                                            is legal, valid and binding for all purposes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Notices</U></B>.
                                            All notices, consents, claims, demands, waivers, and other communications hereunder (&ldquo;<B><U>Notices</U></B>&rdquo;)
                                            shall be in writing and sent by certified mail, hand delivery, overnight delivery or e-mail,
                                            if sent to Spartan, at the address set forth on the first page hereof, e-mail: kmonchik@spartancapital.com,
                                            attention: Kim Monchik, and if sent to the Company, to the address set forth on the first
                                            page hereof, e-mail: rweingarten@lixte.com, attention: Robert Weingarten, Chief Financial
                                            Officer. All Notices shall be deemed to have been effectively given (a) when delivered by
                                            hand (with written confirmation of receipt); (b) when received by the addressee if sent by
                                            FedEx or another nationally recognized overnight courier (receipt requested); (c) on the
                                            date sent by email (with confirmation of receipt from the intended recipient by return email
                                            or other written acknowledgment other than an automatic &ldquo;read receipt&rdquo;) if sent
                                            during normal business hours of the recipient, and on the next Business Day if sent after
                                            normal business hours of the recipient; or (d) if certified or registered mail is required
                                            by applicable law, the fifth day after the date mailed by certified or registered mail (in
                                            each case, return receipt requested, postage pre-paid).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are in agreement with the foregoing, please sign and return to us one copy of this Agreement. This Agreement may be executed in counterparts
(including facsimile or .pdf counterparts), each of which shall be deemed an original but all of which together shall constitute one
and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page of LIXT RD Placement Agent Agreement Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page of LIXT RD Placement Agent Agreement]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Spartan
    Capital Securities, LLC </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 5%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 45%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Duddy</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head
    of Capital Markets</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AGREED
AND ACCEPTED</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing accurately sets forth our understanding and agreement with respect to the matters set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lixte Biotechnology Holdings, Inc.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 5%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 45%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geordan
    Pursglove</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex10-2_002.jpg" ALT="" style="width:650px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lixte
Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PASADENA,
CALIF, July 8, 2025 (GLOBE NEWSWIRE)</B> &mdash; Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the &ldquo;Company&rdquo;), a clinical
stage pharmaceutical company, today announced the closing of a registered direct offering with accredited investors for the purchase
and sale of approximately $1.5 million of shares of Common Stock (or Pre-Funded Warrants).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering consisted of the sale of an aggregate of 974,026 shares of Common Stock (or Pre-funded Warrants in lieu thereof). The public
offering price per share of Common Stock was $1.54 (or $1.53999 for each Pre-Funded Warrant, which is equal to the offering price per
share of Common Stock sold in the offering minus an exercise price of $0.00001). The Pre-Funded Warrants are immediately exercisable
and may be exercised at any time until exercised in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate
gross proceeds to the Company were approximately $1.5 million. The transaction closed on July 8, 2025. The Company expects to use the
net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Spartan
Capital Securities, LLC acted as exclusive placement agent for the offering. TroyGould PC acted as counsel to the Company. Kaufman &amp;
Canoles, P.C. acted as counsel to Spartan Capital Securities, LLC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registered direct offering was made pursuant to an effective shelf registration statement on Form S-3 (No. 333-278874) previously filed
with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on May 2, 2024. A final prospectus supplement
and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC&rsquo;s
website located at <U>www.sec.gov</U>. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained,
when available, by contacting Spartan Capital Securities, LLC, Attention: Prospectus Department, 45 Broadway, 19th Floor, New York, NY
10006, by e-mail at <U>investmentbanking@spartancapital.com</U>. Interested parties should read in their entirety the prospectus supplement
and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in
such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Lixte Biotechnology Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIXTE
Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing
and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated
in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com),
LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIXTE&rsquo;s
lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology &ndash; activation lethality &ndash;
that is advancing a new treatment paradigm. LIXTE&rsquo;s new approach is covered by a comprehensive patent portfolio. Proof-of-concept
clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.
Additional information about LIXTE can be found at www.lixte.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing material may contain &ldquo;forward-looking statements&rdquo; within the meaning of the Private Securities Litigation Reform
Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking
statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding
the Company&rsquo;s product development and business prospects, and can be identified by the use of words such as &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan,&rdquo;
&ldquo;believe,&rdquo; &ldquo;potential,&rdquo; &ldquo;should,&rdquo; &ldquo;continue&rdquo; or the negative versions of those words
or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements
are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks
and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the
underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected,
intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable,
the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security
laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to
actual results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@lixte.com<BR>
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or<BR>
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roger
Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !- /H# 2(  A$! Q$!_\0
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M]U=^(O\ \TU+_P +^^/W_1>?C=_X=WXB_P#S35^V_P#P<8?L(?LM_L _M1_
M7X;?LH?#:X^&7@KQO^S]/XX\2Z3<^.?B#X\EU+Q0GQ(\5Z&NIG4?B)XH\5:E
M9 :/8:?9"RT^[M=/Q;"<VK7<D]S/_/A07&2E%25[.^]KZ.W30]8_X7]\?O\
MHO/QN_\ #N_$7_YIJ/\ A?WQ^_Z+S\;O_#N_$7_YIJ\GR/6B@H]8_P"%_?'[
M_HO/QN_\.[\1?_FFH_X7]\?O^B\_&[_P[OQ%_P#FFKR>B@#UC_A?WQ^_Z+S\
M;O\ P[OQ%_\ FFH_X7]\?O\ HO/QN_\ #N_$7_YIJ\GHH ]8_P"%_?'[_HO/
MQN_\.[\1?_FFH_X7]\?O^B\_&[_P[OQ%_P#FFKR>B@#UC_A?WQ^_Z+S\;O\
MP[OQ%_\ FFH_X7]\?O\ HO/QN_\ #N_$7_YIJ\GHH ]8_P"%_?'[_HO/QN_\
M.[\1?_FFH_X7]\?O^B\_&[_P[OQ%_P#FFKR>B@#UC_A?WQ^_Z+S\;O\ P[OQ
M%_\ FFH_X7]\?O\ HO/QN_\ #N_$7_YIJ\GHH ]8_P"%_?'[_HO/QN_\.[\1
M?_FFH_X7]\?O^B\_&[_P[OQ%_P#FFKR>B@#UC_A?WQ^_Z+S\;O\ P[OQ%_\
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M[_8'A74=?U_PYH_@OQ;I<_Q#UO1?$NSPOJ_B2%=8\$Z)?+<0P0;KC\"/B?\
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MM TR[UB2_P!(\3)-=Z9;:A>Z3::C;>'O%,NA>5>(OV ?'7A/]LE?V%]?^/\
M^RK8?&E/$EK\/K_69O'7Q7C^%VC?%Z_\50^#=/\ @OJWC"7X'1:E!\0[_6KJ
MS6WE@\,77@%;>\@:Y\=V]P)[:$&IIM*V_6Z/A!W6-2[L$102S,0JJ!U+$X
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M+J?67_!M_P"-?AEX&_X*T_LCW'Q U+3+#1];3XJ>%O %WJE[%'H6G_%SQ_\
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MXRN77^67]GO]FS]H[_@H_P#M5VWPD^%'B"3XQ_M ?%^?Q+XW\2>.?BMXWO\
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MXQ^'7PP^#7PS_9Y\!>/?$D%Q;7MMKGQ%\(?L]_#+X4^'?B/K%I>V5KJ%G?\
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MB9H\%OI_Q-Q+]&_\%0H]7\/_  X\,>#/#MK\8=&^'MA\+OV'M6?PK#_P3>^
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MZ\.ZM>QVA:QL_$EG;Z7XQTBQ>2#1/$NFEO,'ZB_&3_@LY^RA^VTK:]_P4/\
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M'X46]C9--).3-XXU&Y\2^.;;4[J65[C5M2\(:QX,76M0DGU+4+*2ZE#)A_\
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M_GL4 ?C_ $5^P'_#I74/^CA[/_PSL_\ \]BC_ATKJ'_1P]G_ .&=G_\ GL4
M?C_17[ ?\.E=0_Z.'L__  SL_P#\]BC_ (=*ZA_T</9_^&=G_P#GL4 ?C_17
M[ ?\.E=0_P"CA[/_ ,,[/_\ /8H_X=*ZA_T</9_^&=G_ /GL4 ?C\W0_0_RK
M^JO]F;_DV_\ 9^_[(C\*/_4#T&OS4/\ P25O\,?^&A[,X5CC_A3L_. 3CCXL
M@\XK^A/X$_L0W?A_X(?!O03\58+O^Q/A5\/-(^U_\($]O]J_LWPCH]G]H\C_
< (3:?R/.\GS/)\Z;R]VSS9-N\AE/XODOS9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex10-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "$ N,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO+/B;\2)-%D?0
M]%D ORO^D7 Y\@'LO^U_+ZU=.G*I+EB9U*D:<>:1TWBSXA:+X4!AFD-S?8XM
M82"P_P!X]%'U_*O'M<^+/B;5G9;:=-.MST2W'S8]V//Y8KAY)'FE>65V>1SN
M=V.2Q/<FI;.RN]0N!!96LUS,?X(4+']*]BGA:=-7EJ>14Q52H[1T0MW?WE_(
M)+R[N+EP,!II"Y ^I-112R02+)%(\;J<AD8@@_45U%O\-_%,Y :PC@R,CSIT
M7],D_I4EQ\,O%$"@K:V\V3_RRN5_KBMO;4EI=&/LJKULRGIWCSQ3I;AH-:NG
M .2D[^:I^N[->\_#_7M4\1>&HK[5HX4F<DIY2D;T!QN//<@\>U?/R>$]9_MF
MTTVZT^XMY+F41JSQG;CN0>AP,GK7TYHMA%I^EP6\*[8U154>B@87]!7!C'3L
MN5*YWX-5+OF>AHBBBBO-/2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[=O[#U-_-T^5ND;DXVY_3\CWKJDDY3Y=_P!.IS1;48<VQZK124M<AUB4M%%
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M9N[[6)83E!>RYC!]=B@+G\*Z@*%4*H  & !VI:*3DWN"BEL%,D4O&RJY1B"
MP'(/K3Z*11R^D>"H-&UJ75+?5=1>>X.;D2R!EG(! W#';/&,5U%%%-R;W)45
M'8Y+5O 5EK.NKK%SJ6HK>1$&W:*0*(!Z+QZ\\YZUTUG#);VD<,MP]PZ#!ED
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M _[;:_\ /Q%_WT*/MMK_ ,_$7_?0IG]FV7_/LGY4?V;9?\^R?E0 _P"VVO\
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M[;:_\_$7_?0H^VVO_/Q%_P!]"F?V;9?\^R?E1_9ME_S[)^5 #_MMK_S\1?\
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M]"C[;:_\_$7_ 'T*9_9ME_S[)^5']FV7_/LGY4 /^VVO_/Q%_P!]"C[;:_\
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M1110 444TNH."P!^M #J*3-+0 444A.* %HI,YZ$&C< >2* %HHHH ***:6
M)R1^= #J*0'/(((]J6@ HHHH **0G'4XH!ST.: %HHHH **0G%&X>H_.@+BT
M4@.>AI: "BBDH 6BF[@>A%+0 M%%!H **;O7^\/SI=P/0@T!<6BBB@ HHII8
M+U8#ZF@!U% HH **** "BBD)Q0 M%)N!Z$4M !1110 44A..IQ0&ST.: %HH
MHH **** "BFEU!P6 /N:6@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M-PKA?'5A9R>(/"L\L$9>74A#*Q'WTV,=K>HR!UKNJX;Q^]HVK^$K>Z>':^J
MM'(PY78W./3)%:4OB_KL9U?A%;3H]+\?Z6N@$Q0SK*=2M8FS$J!?E<CHK;L
M8ZC-=Q7G]Y''X#\4+K%LBIX>U0K%>A!E;>7HDO\ NGH?SKO8Y$EC5XW5T89#
M*<@T3Z,5/JA]%%%9FIRWQ%MX9O 6LO)&K/#;/)$QZHP'!![&MC0K>&UT*QB@
MB6./R$.U1@9(!)_.LGXB31Q?#[7#)(J;K1U7<<9)' 'O6SHTD<NBV+1NKKY$
M?*G(^Z*T?\->IG]OY%ZBBBLS0S]9T>UUVP^PWH9K<R([HI(W[3G!([<5P/B#
MPCH5GXO\+V=O8".WNYIEGC$KX<",D \]CS7IU</XKN8$^('@V-IXU<3SDJ7
M('E$9K6FW>R\S&JE:[\C=TKPII6AZ@]WID!MC)%Y<B!V97Y!!Y)Y&#^=;=%%
M9MM[FJ26P4C*&!5@"",$'O2TAXYI#//_  !9VT7BCQ>R0(IAU#RHL#_5IC[J
M^@]A7H-<#X!GA?Q1XT1)8V8ZGN # DC;UKOJTJ_%]WY&5+X?O_,*#1169J>=
M/I>A_P#"U-32^@M5A;3890LK!5,A=@6 )QD@"NGT#2=%L[N^O=%9-DQ6*5(G
MS&'3/(]_FYQZ5S[Q:5>_%K48[];.8)I4.U9]K;6\Q\X![XQ70:)<Z!;7<^CZ
M++"S*SSRQ6^&2$DC()'"DGG;UZUM/;Y(PAO\V;U%%%8FX5YSHNL>&+VYNK'Q
M(;<:X+F1)8]149(W';Y>[@+MQ@"O0Y2XB<QJ&< [5)P">PKF(_\ A&?&NDK-
MJ%K8SNN8YHY=N^&0<,N>H(/^-:0:L[F<T[JQK:#I,>CV4MO!<R36SS-+!O<O
MY:$#" DG(';VK4KD_ EJ;*QU"WM97DTB.[9=.+L6(CP,@$]5#;@/I76=!4RW
M*A\*"BLW1M<T_7K:6?3I_-2*5H7RI4JR]00>:TJ333LQIIZH*9-%'/$\4J+)
M&XVLK#((]"*?2,P498@ <DFD,X?X8V=O!HVHRQ1!9#J=S&6ZG:LA"C)[ =J[
MFN$^'>HV,/A_4VEO+=%35+MF+2@;1YA.3SZ5UNF:M9:Q!)/83">!',8F7[CD
M==I[CW'%:5$^9LRIM<J1>HHHK,U,KQ+;0W7AO44GB611;2, PS@A201[BL?X
M:PQ1^ -)D1%5Y8=\C8Y=LGDGN:V_$#I'X<U-G8*OV67DG ^Z:YWP%JVG6/PV
MT>:ZO[:"-+?YGDE50/F/7)K5?PWZF3M[3Y':454T[4(-4L8[VU+-!+DQLRXW
MC/# 'L>HJW61J%<YXOUBZTVSLK33V1+_ %.Z2T@D89$><EGQWP <>^*Z.N.^
M(5A>R6.FZQIT!N+G2+M;KR5&2\?1P!W..?PJZ:3DKD5&U%V-B'PMHT<*I-8Q
M7<F/FGNE$LCGU+-S2:3H]QI.I7@2\EETR5$-O;RN6,# G<%)YVGY< DXJQIN
MNZ9JUC'>6=Y"\3C^^ 5/H1U!'H:33]<LM5OKJWL9//6UVB29.8]QS\H;H2,<
MXZ9%+WM;A:.AIT445)84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% "'K5!=%TI)O.73+)9=V[>(%#9]<
MXZT44)BL7Q2T44#$J*YM;>\A,5U!%/$3DI*@9<CV-%% BF/#^B_] BP_\!D_
MPK04   # '2BBBX62'4&BB@8E9\FAZ1-*\LNEV3R.269K="6/J3CFBBGL*U]
MR]'%'#&L<2*D:C"JHP /84^BBD,**** *MWIUC?[1>6=O<;<[?.B5\?3(IUK
M96MC&8[2VAMT)R5BC" GUP***!6ZEBBBB@853NM,T^^D$EW8VUPZC:&EA5R!
MZ9(HHH F-M UM]F,$9@V[/*V#;MZ8QTQ[4L%O#:PK#;Q1Q1+]U(U"J/H!110
M!+1110!!=6=K>QB.[MH;A <A98PX!]<&BVM;>SB$5K!%!'G.R) HS]!110!/
M1110 52GTG3;J<SW&GVDTQQF22%6;CIR1110(NT444#"D*AE(8 @\$&BB@"G
M;Z3IMG,);73[2"4# >*%5./3(%7*** %H-%% &?+HFDS2-++I=E)(YRSO;H2
MQ]2<<U/:V-I8HRVEK!;JQRPAC" GWQ111=BLBS1110,*H3:+I4\[33:99R2L
M<L[P*6/U)%%%%Q6N7@ !@# ':EHHH&<]X0C1],N+_:!/?7<LLQ48!(8H,?@H
MKH:**<MR8_"@IDD:2QM'(BNC AE89!'H1112**'_  C^B_\ 0(L/_ 9/\*NP
MPQ6\2PP1)%$HPJ(H51] ***+MBLEL2T444#(;BV@NXC#<P1S1'JDB!E/X&J?
M_"/:*>NCZ?\ ^ R?X44478K(T%4(H50 H&  , "G444#"D-%% %&;1-*N)FE
MFTRSDE<Y9W@4EC[G'-6XH8K>)8H(TCC485$4* /8"BBBXDD24444#"BBB@ H
9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex10-2_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-2_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !=!P # 2(  A$! Q$!_\0
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M917'V6N>*?"_C>QT76[Q;^TO3A'QS]0?:O2]3U"/2M/EO)8Y9%3^")"S,?0
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M_/\ +7SBNTOCG;Z9]*;EKJ2H/E/++L?%&SLY[J6[LQ%$A=CCH!7?^%+N[O\
MPKIMW?G-U+"&E.,9-8_CV\FEMK+0;-C]IU.81MCJL0^\?IBNLMX%M;6*WC&$
MC0( /84Y2O'8J,;/1G':DOB_7KZ9-,G32;")BBO(N9)B/XAZ"L/0/$7B71O'
M<?A?7YUO$N%S%,!STSG->HBO-[>W;Q!\8I;Z-?\ 1=(B\LOVWD<BB,EK=:$R
MB]'?4]) H8<4"EQ63-CSWQGJ?BF3Q-:Z1X9*HRPF6=F'RX/3)K%OV^)^GV,]
MW/>6:Q1(78X[5ZP(8EE:4(HD8 %L<D"N0\>2O?C3_#5LX$VHS R>T2G+'],5
MI&71(QE#6[9N>&[J[O?#MC<WI!N985=R!C.:P&U/4_%.OWECI%\+'3[!MDMP
MJ[GE?T'H!78PQ);P1Q1KA$4*H]A7D%_J.H?#;QG>R0PB^T[4CYIB4Y>,]S@4
M15V[!)\J29T5]?Z]X*U6RDO[\ZEHUU((7>1,/"QZ'/>NYNIG@M))HH7G=5RL
M:=6/H*\Q@\3VOQ+UBSTT;;2SM95N)8IF^>=AT5:]4 Z#L.E)JSVU'%WVV/,%
M\6^([KXG:9H=[;KI]JVYVB1MQD&TD9/]*]/'J>*\PUDX^.^A_P#7!_\ T$UZ
M@RAD*D<$8-.2VL$7O?H<+9WNK^-+J[GL-2.GZ5!*8(S$F9)F'4D]A3;;5=;\
M,^+++2-8O!J%CJ)*6UP4VNCCLU<C::_?_#'7;[2)K?[?ILLC7"-%R\>X]\=/
MQK>T36K7XB^*;.^#);V^E$R1P,W[R5SW(]!5.+2\C-23>^IZ?111TK(Z@HI"
M?>DH$.K'U^RU6\L\:1J(L[A,D9C#!SCH?2M?/%)_C0M!2U1X?X;\5^-/$?B*
M714U.&%XBPDD,><;3@UUFLZ9X^LK&2YM->@N#$N\IY.TG'7%><^#M=M/#WQ$
MU*[O0_E--,O[M2Q!W'L*]%E^)-OJ/B;2=)TP2"*XEVSO-%C</0 UT23Z(Y8M
M/=G9Z!>/J.@V-Y-_K)H59N,<]^*TCC-8'B3Q1IOA&PCEN@<R,(X((QRQ]![5
M@7OQ+_L6]MX=<T6YL8K@ I*6##'OBL%%RV.AR2>IW_2BL;5]>73=&_M2"UFO
MH-H?]QU"GG.*Y[0OBAI_B+5XM-T_3[IYG!+%L (HZDT*+M<;FMCNJ6N0E\<B
M/Q&^AIH]Y+=JP'R8*[3_ !$]OQKK<FDTT--/8CFD\N)W"L^U2VT=3CM7"75G
MX\UPO<PW\.D0'_4VV,OCMN-=^0#S3798T9W("J,DGL!3B[=!25^IYUX"\6ZM
M<:_?^&=?PU_;9*R 8R!U!_2NXU2[O+.SWV-D;R<G CW;0/<GTKAOA_:#5_%6
MO>+'CVQW$QBM\^@X)_'%>C[0:J339$4U$\Z\"^)]9\0>*]8AU,)"EJ-BVR=(
MSGU[_6O0+J9K:TEF2)Y7121&G5SZ"O,_AR?^*]\4_P#74_SKU/O1*U]-@A>V
MIYW<Z;\0=61[Q=3@TTGYH[1!G:.P8^M/^'7B[4]8N;_1M;0?VA8M@N!C</?W
MKN[FXBM+66XE8)'$I9F/8"N ^&6GR7,^L>*)UVMJ=P?*&/X <9_&G=.+NA<K
M4E9GHM(!S2]J2LC8\MO=1\>:UX@U%O#[QQZ;!)Y4?FKC)'7Z\U5N+SXCZ5>:
M>+ZYM2ES<K"%1<EB>U>L1PQ0@B*-4!.2%&,FN-DN#X@^(Z6JJ#:Z+'YDC>LK
M=/RK93OI8P<+:W.ON;A;.REN9CA(HR[?@.:XO2O[?\7V;:K_ &L^F6DK'[-!
M @)VCHS'OGTKL-1M%O\ 3+FS?[LT;(3Z9%>/:#XVO? *W&@:K9M=VUHY\NX@
M;=M!Y )Z?A4Q5UYCG*S5]CM= UW5K'Q7)X7UR1;IVC\VUNU7&]1U#"NON[E+
M*RGN9#A(D+DGMBN"\'SQ>,/$DGBLS1J(HC#!:@_.@[EOK72>-8[Z;PC?V^G0
M&>YE38$'4@]:&M;#3TN<';'XG:M$-0M+J!+>?+1*W!"YXKM_!^GZ]9VDTWB&
M\^T7<S#"J<JBCTKBV\=^+/"]C:QZKX42*SC15\R.0L0!Z]@:]$\.^(;+Q-I$
M>HV+$H_#*W5&'4&JE>U[:$P:;WU->D8GI2BF32)%&TDC!40;F)Z "LNIMT,K
MQ%K]IX;T:;4+M@ HPB=W;L!7/_#3Q!?^)='O+^_DW.;E@BXP$7T%9L*MXXU"
M]UNYC;^R+!7CLHFZ2N!S(:/@W_R+E[Z?:G_G6B2Y?,RYFY>1WNI7BV&F75VQ
MQY,3/D^H'%>76H^*&J6T=];W5O'#./,13P0IZ5W'CVWO;GP?>V^GV[3SR@*$
M4X)&>:XN3Q_XJ\,6MLFK^%(X+*-%3?%(6( &/H*(J^PIVOJ=KX/T[7+*QFE\
M07WVF]F?.U3\L:]@*U=7U6ST/3);^^E$=O$,DGN?0>]1:!KEGXCTF'4K%]T4
M@Y!ZJ?0^]>9>.M:74_B)I^B2)+<6=F1(]M%R99.P-)1N[%.5HW1U6FGQ!XN9
M;^>XDTG2&YA@BXFE7U9NV:[6*,1Q+&&9MH W,<D_6N O_B!J/AZ6+^V_#<UI
M8.=JS1N'V_7' KN;.\@O[2*[MG$D,JAD8=Q2DGOT'%IZ'&>,[[Q-/KEOI'AA
MXXY%A\^=V'0$X%9NEZ1\1;C4K=-6U..*Q#[I3"V&(]!1J5[XQTSQEK%]IGAY
M+ZW*HB22R[?E SP._-7/"GQ+76=6&D:MI[:?J!^ZIR 3Z<\U>MM$0[.6IDQ>
M#?'=IK-]J5GK%K'/=MEWV9X[ 9Z"N6O].\7?\+(M;6758SK31'R[D*,*N.F/
MI7T#VKR_4K>9_CKITJPN8U@RSA3@?*>].,[WN*=.UDF=SX:TRYTC0+:RO;IK
MFZ0$R3,<[F)S6MGWJKJ#7B6,C:?'')<CE$D;"M[$US-QK/C*5/(M?#<$,YX\
MV6Y!13Z].:QLV;74=#D[RT7_ (7Y;?8E  A62XV<#/.<_I7KOTKEO"OA'^QI
M[C4]0G^UZQ=G,\YZ+_LK[5U7:KG*]EV)IQM=OJ-)Z5Y=\10&^(/A,$ CSUX/
MUKU$BO*_%_AWQ?KOBVRU6RL;6*/3V'DAYL[\'.2.WTHIK4578],EL[:=6CFM
MXG1A@JR @UY=X3LV\._%[5-&LF)L)H#-Y8/"$]*ZD:UXSDC\M/#-M',1CS'N
MQM!]<8J?PMX3DTF\N]7U&<7.KWIS*X&%0?W5]J=[)W%:[5CG/C3&DNAZ.K*"
M&U!%/T(.:[VPL+2"RM/+MHE,<2A"$&1Q7'_$K0-=\20V%GI=I"T=O,+@RR28
M^8=%Q75:#+JDNGJNJV,=K/& FU)-X< =<]J&WRH$DYLX7PU<&\^+^N-<MNEB
MCV0AOX5]!7?:W:0WVA7UO.@:-X6!!&>U<MXD\'Z@OB*+Q/X:>--27B:&0X29
M>_/K5F[NO%.L6!T^/2(]/:9=DUQ)-D1@]2HQS2WLT%K)IF7\(9I)_!T]O.S/
M%',\:[CT7TS5O1M2TK1WNM(\,V=SJ3)*6D56Q'&QZC>>*Z#2/#=KH?AW^Q[-
MF"LC*TAZEF'+5Q7A'1_%_@\7.DQ:;;WEM)*7CNFFVX![GCGZ55U)MH5G%)#/
MA3N_MKQ)OC$3>?EHPV=IR>,UI2W:R_&J"WN#Q%IY:!6Z;CU(JOX8\-^)_#'B
MB]<06MY97SAY)S)L*\Y.!_2KWCGP9>ZM?6FNZ',L6KV>-NXX#J.V:;:YGYB2
M:BO(ZC7E#:!J"LH(-N_![\5ROPA_Y$"UP?\ EI)C\Z2,>.-:TVXLK^SM+%6B
M9&F5\LYQV';/K3OASHWB/P_I::9JEO;):H69623+Y)Z$4K+E:OJ4FW)/H8WB
M)1X1^*>GZU$I%KJ8\FX Z;NF?ZUG_$BYN)]>36=.0/#H;QK-(O5F8]/H!S7=
M>/O#,WB7PT\%K@7T+"2W8G&&%,TKP;':>!I-$F.^>YB)GD;G=(1UIJ:5F1*$
MM8E2_P!0M_%M[H>G6VV>UD5;ZX/;:.@/U/\ *M3QE:Z'/HZ/KLQAMH)%D1E.
M"&'3 [UG?#;PG=>%](F%^ ;R5\<'.U!]T9IWQ(\,W_B/1;==-V-<6TXF".<!
M\=JG3FL79N-V<Q\2-9GU;P*[Q:3/'8;TVW4[!6//!"=>:]%L[6&]\,6UK.NZ
M*:T1&'L5%<9K6C^*_&/A5M,N[.VTXQJ#GS-QF8=!C^$5U/A1M;72(X-:LX;>
M6%5C0QR;MP QSZ4V_=2[$I>\V<1X U)O"NIZYX8U&0*EH6G@<]"G7_"NP\%6
MP_LB74WC"SZE,UPQ/7!/R@_05R/Q&\-#4/&&AO:S&*:_8V]P%ZF,<DUZ;%;+
M!9K;0XC")L3 ^[QQ2D[Z]RHIK3L6 1TI0<UYAX$&M:?X^U[2-1O7NHD43AR<
MC+'@^W':O35SW-0U9V-(RYE<<>E<=\3_ /DGFJ_]<Z[$]*XGQWIWB+7M-N=%
MTRQM?LLRC=<S3X/N N*<;75PGL:W@LX\$Z+_ ->B?RI/%/A/3?%EBL%\A62,
MYBF3AD-9_@^U\4:3IUII6JV5FUO;IL%Q#<9( Z?+CFMK6]2OM/MU_L_3);^X
M?A54X5?=CVH?Q71/V=3SCQ9H4GAGPI)#>Z_>WRR?NK6T)QN8^O<X]*[#X>>'
M3X<\(6UO*N+F4^=-D=&/:H-+\)7E]K$6O>)I4GOD'[BV3F*W'MZGWKL\8JI2
MTL3&&O,>=6W/Q[O<CC^R$_G7H?((QTK@=>T77]/\?CQ1HMI%>I+;"VE@=]IP
M/2NDL[K7_P"QY[J\T^#[;UBM8I>,>A:E+6S&M+HXGX3PQ_VGXGGV#S?M[KOQ
MSMW$XI/BHBQ:]X9ND7;.MR!O'7%3^!=%\3^'-3O6O=-@:VU"X,SM'-S"2<],
M<U/\0?#WB#7]7TUM,LX&@L6$OF22X+MZ8JXNTB+>[L>B(<HI/H*4GVJEI4][
M/81O?VBVMQT:)7W@>^:NFL>IT;H\\^,O_(DGWF6ND\.Z982>&]/+V5NQ,"Y)
MC'/%<_\ $G1/$7B6R32],L[<VN0[322X)/IBMOP<FO6^F1V.MV4$)MT"1RQ2
M[M_X=JTO[AC;W]30TC0[;1#=BTRL5Q,9O+Q@(3V'M7!7/_)=K?\ Z]A_*O4J
M\OO_  _XO?XB'Q':Z?9F.(>6D;SXWH/?'!-$-;W":M:Q/\8+EX])TJ D^1->
M*)1V*^]>@V@1;*W$0&P1KM ],<5B^(_#B>+O#@L=00VTY =2C;O*?Z]ZR=&N
M/%^BV*Z9>Z3%?^2-D5S%-M#J.F[CBC>-@VDV85TATKXXVYLCY:WL&9T7HWN1
M4NI7/VGXVZ?;79S#!!N@1CQN/?ZUTFA^&;C^WIO$>M>6VIR+Y<<49RENGH#W
M/O4'C/P9-K=Q:ZOI4PMM9LR#%(> X]#3YEL+E;U.OEB69&C<95P58'N#7F'P
MK9[77/$>F1D_9(;DE!V!SCBNCCU3Q?-9?9SH4,=Z1M,QG_=@_P![I^E7_"WA
M:+PU8RCS#/=W+F6XE/\ $Q]/:I7NJS*?O--''^,[6&Y^+/AR.:-67R\G(ZD'
MC->E1VMM#*TD4$<;MP65 "1]:\\\3:%XHOO'5GK5A86[P6 VQB2;!E'4_2O0
M+&2YN+1)+RV%O.?OQ!]P'X]Z<GH@@M66JIZM_P @>^_Z]W_]!-7:PO%!UI]*
M>VT6TAFGG4QL\LFT1@C&?>LUN:2V,WX<(K?#[3E90597!!&01N-<1XGT2_\
MAUXA'B;04W:;,V+FW'1,]<^U=EX"L/$.B:7%I&K64"PP [+B*;=NR<X(Q76W
M%M#=VLEO<1+)#(I5T89!!K7FY9/L9<O-%=SA?"^M6GB#QO=:C9ONBDL(LCNK
M<Y!K(^(TUQ/X\\.V(NFMHLEED R%;/!P>*V_"'@63PGXHU*>!E;3KA08>?F4
M]U(_K5WQWX+'BRQB>WF^SZC:G=;R^_H:<914KD.,G"Q!J?@S5M8T^2QOO$D\
MUM*,,AB7G]*UD\+PIX,;P])*T\?D&(._7V-<UI<WQ)6)+"XLK+>ORF\D?(QZ
MX[FN[L+:>ULHH;BY:YF ^>5AC<:AZ:&J5]3S/P#XA&E^$M6TS46_>:2S1JK=
M2IX5:H^ +VX\+>*[[1]5"P1WL/VQ.>$[[1^%;NH?#V6Z^(RZHC;-)EQ/<1AO
M]9*O0$>E3>/_  -=>)-4TJ\L=J&-_+N#NP?+_P#U<5I>.W<RY9;]C6\'0B]>
M_P#$+)^\OY<1$CGREX7\#UKJ@*CM;6*SM(K:!0L42!$4=@*FK%N[N="5E80C
M@UR'Q,4-X U3(!Q'D9KL.U<;X^L==UG1I]'TJQADCN%P\\DNW;[ 8YIPW1-3
M5,?\.% \!:;CCY":Y[QS<A_B5X6L;IO]#(,NT]#)NP*Z#P)9:WI&CQ:1JMA%
M$MNGRSQR[@_MCM2^-O!@\4VD$MO/]FU*T;?;S$9Y'.#[55US$--HZL@$$,!@
M\8/>O,/ ZR:5\3?$FD6JXT\MY@3/"-_DFNALM5\8)9+;7.@PO>HNT3BX_=L?
M[W2KOA;PPVA&\O+N<7.IW\GFW,P&!GL!["I^&]Q_%:QQ?Q6@CN?%7A9)4#(T
MI# CJ-PKU!;2WA??%!$CXVY5 #CTKSWQWX>\1Z]XCTVZTVR@\C3FW*\DN#(2
M<].W2N]TV:\N;%)+^T6UN3D-$K[P/QIMZ(26K/*?'=W?6/Q7T^YTVV^TW:6+
ME(SW-;_PPO;+5[.YOKB0RZX9"+II?O+ST4=EJIJ7A_Q?=_$"'Q)'867E6H,4
M4+7&"Z>I..M3ZQX-UBWUVW\3^&TAMM0?F[M'?Y']>>]:.2<>4SY6I<QZ,#BG
M9%9&G2ZO>Z7(-0M8K"[(*J8Y/,'3[W_UJXKX93:O;ZWK^CZA>R726LV5=CD!
MCUQ]?2L;:7['1S:I(]-ZTAZ&D7D55U.6]AL)7T^V2XN0/DC=]H)]S2*.6\##
M_3O$8/\ T$&K!^(/@VYM;Q?%?AP&.^MSOFCCXW@=\5H^#=-\7:-JUZ=3L;22
MVOY_.>2*;F(GKQCFN_VYX(X]ZU<K2NC'E3C8\FT_QA;^+O$'A:8#R[R*1UN(
MCV;;U'L:]9;Z5Y\_PZ%A\0[+7]+5$M"S-<19QM8CJ/K7H)]JF;6EBH)VLSF_
M'L22^!-9#J&"VS,,]B*S?A.,?#VRXYW-5WQQ:ZWJ6ASZ7I%G%(+J,I)+)+MV
M#Z=ZJ?#W3=<T'2$T?5+")(X<LL\<NX-GMCM1]DG:1VHZ4M%%9=3:V@'I7F5X
M?^+^6W_8.']:](NGFCM97MXA+,JDI&6VACV&>U>8W'A[QO/X[C\4"RTY&2,1
M"W^T_P 'H3CK6D+:F=2^ECLO&]HU[X+U2% 2Y@) 'M63\*M4CU'P-:JK@O;D
MQ.O<>E=79&ZN;'.HVD<$SY#Q))YBX^N!7G8\(>(?!OB&XU'PLL5U871S+92-
MMVGVIIIIQ8I7336QM_$YO,\)BT7F6YNHHT7U.ZL'XK6\UAHF@7Z D:?.F\^F
M0!_2NFT[3-8UO4;?4_$5M!;I:DM;6D;;_F/\3'U]*W-;T>VU[2+C3;M<Q3+C
M/=3ZT)V8G'F1-IU[#J&G6UY;2"2*:,,K#N*Y76H_M?Q,T"-#DVT$DSX[9X&:
MQ=#T[QQX,C?2K6TM]5T\,?L\C2;"H]_05UV@:'<6EQ<:MJ;))JMV )-GW8U'
M1%]J-F-.ZV.)U2<>'OC;:7=R=MOJ,&S=Z'H/UKU7-<IXX\%Q^+=.C\N;[/?V
MYWP38Z'T-9>G7'Q"%JFF7&GVBR!=AO\ S>%7IG'<T-)JX*\;HO>$X3)XN\4W
MP_U3SK"I'<J.?YURWP_C2'XG^)8YL>>69DSUQGM7I.AZ-%H6EQV43,Y!+22-
MU=CU)KEO$O@V_'B"+Q-X:DCCU-.)H9#A)E_QJHR6J)E%Z,UO'FE6^K^#M0AN
M%!"1&1&(Y4CFH?AG+-/\/-(>X9FD,1!+=?O'%4;J/Q5XIM/[-N].CTFTEXN9
MO.WNR]PH]Z[*QM(;"SAM+= D4*!$4=@*ENT>5E)7ES%BN9\=ZOJ&A^$[J]TR
M+S+E, $#.P'^+%=/3&164JRAE/8C(-2G9W-&KJQYW\*?$^M^(K.\&KYE6)AY
M<Y7:6]J]&%,CACB7;'&B+Z(H%/'%.33=TK"C%I6;N!Z5'-S _P#NG^52-TXK
M$\22Z\EELT*S@GED!5FEDV[/?'>I6]ARVN>3_"@ ?$S6,GDPR8_[[%>T7\K6
M^G74T?\ K(XF=?J!FO&]#^'OCKP_KPUBV^P--DEU:;AP>H/%>P:8]]<:<CZI
M:QP71R'CC?>OYUK.VYC"^UCQ7X72:KJ.M:R;348[>YD_>2&1-Q?+&NX7X>3R
M>+K;Q%>:P[WD3AB(TV@@=JY[5/AYXB\/>*6UKPFZ/&[%C$S8*YZKCN*ZS1M/
M\6:M<0W'B.>*T@@<.EO:GF1A_>/I[4VUNF0HO9HP?CE_R*EI_P!? _D:[OPB
M?^*1T?\ Z\X__0:Y3XE>$]>\7&TL[!+5;.([VDEEPQ;Z8K9\%6?B'2]-CTS6
M;>U$5O&%BGAEW%L=B,<5.\=S574CJ]PI&954DD #DGTI<5RWCBU\17VBFR\/
MK$))\K+([[2J^U9I79K)V1GV,"^,/%W]L.I;3-,)CM >DLO=_H*[;S$$GE[U
MWXSMSSCUKRO3M+^*6FZ;#9VITM(8$VHI;DBNM\':#J6GP3W^NS^?JUT?WC!L
MA%'11[5<DM[F4&]K&?\ %S'_  KV^Y_B7^=;7@C_ )$O2O\ KB*QO'VE>(O$
MFFSZ+I]A:BV<JWVF6XP3CL%Q5WP=:^)-+TZUTO5;&S6"!"OVB&?)/I\N*;MR
M+N"3YWV.IEE2&)Y)&"1H"68] *XS0K7_ (27Q++XIGR;2#,.G(1QCO)^-2?$
M+3O$NKZ6FG:"D(BF_P"/AWDVG'H/K7-V]A\5+2P2VMSI4<42[$0-@@"A1TW!
MRL]CU-9$,A0."XZJ#R*>*YSPAH5UH^G/+J4YN-4NF\RYE+9R>P'L*Z,5G*R=
MC2.UQ.HKB-5!\7>*(M'5-VDZ>PEO&[22#[J?XUT?B/\ M8Z'<+HBQF_8;8S(
MV N>IKS71="^)VC69M;1M-5"YD9I7RS,>N3WJXJZN9SE9V/6MT<>R/*J3PJ]
M,_2L;Q1X4TWQ58"VOD(>,[HIDX:,^U8_A'0O$(U*;5_%-TLMV%\NWBC;*1KW
M(]S70ZWJ5[IUNGV#3);ZX<X5$.%7W8]J76R*W5V><^*- ?PSX3FCOO$%[>1L
M/*M;0M]]CT]SBNL^''AZ3P]X1MX9TV7,Y,TJ]P3VJ+3/"5[J6K1:[XHD26\B
M_P!1:1G,4'^)]Z[/FJE+2Q,8:W8 \UY7\:K.!M(TVX2-1?&[$<;#AF!'2NLN
M-2\4V%S,AT:'4(2Q,,L4VPX]&7''UJA;>%]2\0:Y!K/B<1QK;'-M81-N53ZL
M>YHC[KNPGK'E1UNE*Z:19I+GS! @;/7.T9JWT%&*".*SW-+65CRJ2Z&@?',F
MXR(=1MPB-VW'I_*O4^]<CX\\%GQ79P36LWV?4K0[X)<=?8UGV<_Q GM!IEUI
M]I$Y7RWOO-S@="0.YJ]))-&>L7:VA>\&KY^N>)-2QA9;L1(1T(48/ZU2^,''
M@*?_ *[1_P ZZ[1](@T72XK&WR53EG/5V/5C]:Y/Q]H_B3Q/I\ND6%C:):EU
M87$MQ@MCMMQQ1%KFN$TU&QU/AW_D7-._ZX)_*M">XBMK>2>9PD4:EG8] !7.
M^%(_$=E8V^GZQ96JQP1;1<13[BV.GRXK.^(>F>)]:L(].T-(5MGYG9Y-K-CH
MOTI6O*W0J]HW'>'+,Z_K\_BRZ5O*P8=/1ATC!Y?\:[)949VC#J77[P!Y%>7Q
MV7Q6@LTAA;2HT10JJK8('M79^%-"FT;2O]-E:?4;AO,NI2V=S^GT%.27<F+?
M8WB<G KR[XSV-J^BZ?=JJ_VB+M(XB.&92>?KVKJYM0\4Z?/+&='AU"+)\J:*
M;8<=@RXX^M9]KX7U+7==@UOQ/Y:?93FUL(FW+&?5CW-*.FI3UT.LTN.9-*M$
MN"?-6%0^>N<<U=I*6I9HM!",UXQXK^#U[=:Q-=Z+-$()V+F*0XV$]>:]HIN*
MJ,G$B4%(X_P!X)7P=IDR/,)KNY8-*X' QT KL>U&**3=]1I)"$XK@/$DW]H_
M$C1M$N6/V%8C<&(_=D<= ?6N_-<KXO\ "L^LO::GIDPMM7L3N@D;HX_NM[4X
M63)J7:T+FN^$](\0:>]K>6<?3"2(H#(>V*Y/X3M=VG]LZ)-(TL-A<;(G)Z>U
M:HU7QQ+;BT_L"UCNB-INC<?NQ[XQ6SX8\.1^'=/DC\SSKNX<RW,Y'+N?Z"J<
MK1:9"C[R:)O$NK+H?AZ]U!C@PQ$K_O=OUK"^%]H\7@V*\FYGOI&N)">I)-1_
M%6UO;WP+<V]E$\KLZ[D09)&:VO!BS1^#],CG@>"5(0K1N,$4FO=&G[YNXKS7
MQC<G7/B#H7AN,EH87%S<@=NXKTHUY7I%GJ5K\:]0N[BPF>VGC,<<P'RH#R#G
M\*(=7V"?1'J@&!@=*4# H'6E-9FJ$KA/BCK,FG^'X],MC_I.IR" '/(0GYB/
M>N[KRWXFV5_/XJ\.W%M:37$,<GS"-<XYJXJ[(GLST/2+&/3='L[*(82&)4'X
M"KOU/UI$SY8R,$@<>E,N YM9O*_UFP[?KBD]05TCSOPQ=MXD^)VK:FQW0:?'
M]GM_1<GFO2!7F'PCLK^REUI+VSFA+W!8.ZX#<FO4.1VIR%#4P_%.LOH^D,;8
M"2^G/E6T8ZLYXS]!UH\+:$/#VBK!,XDNI"9;F8_QR'DFN&US1?B!>>,/[7LX
MK)5@REJLDNY54]\>M3MH?Q&UBXBL=8OK2'3G;_2'M6^8KZ?C5N*M9LGG;=['
MIJ,KJ&1@RGH13C45M;QVMM%;Q+B.)0BCV%2DXK'<VL(2%!)/ Y)KS?PC.WB3
MXBZYK1)>"RQ:P<\#W%>@WJL]C<+&/G,3!?K@UYS\&K*^L-,U2"^LIK>0W (:
M1<;^#_*K7PMF<OB2/2)Y#';RR@9*(6Q]!7"?#>.+4[*_UB\Q<7UQ<NCNXR54
M'A1[5WY&X$$9!X(-< OA[7O"&JW-QX=ACOM-NG,DMG*^UD8]U-$;.Z"2>C,C
MXF^$;/3[1?$NE+]CO;>52WE<!N>OUKTK1[F2\T>SN91B66%78>^*Y2ZTO7O&
M4D,&LV46FZ3&XD>%9=\DQ'0'T%=G(KPVY%O&"R+\B9P#@<#/:FWHEU$DD[]#
MS/6<?\+WT/\ ZX/_ .@FO0-=NY+'0;Z[A_UL,+.GU KSV^\-^-KWQO:>)DL=
M.B:V7:L!N<\$8.3BO1+5;K4-->+5K.*!Y 4>))?,&T^^!0[: DW<YKX=V%I/
MX/@OI42XNKW,MQ+(-Q9B>A)KDO'?ANW\+:WIGB/0P;65[E4DB3A3D]0/?TKH
M;#2?$O@JXEMM)M8]4T:1R\<32;)(2>WN*M)HFL>)]6MKOQ#;0V=A:.)(+-'W
MEW]7/MZ4[[N^A'+LK:G:QL6C1B,$J"13J4# H-9G2MCS?XK^*-<\.6=B-)W0
MK,QWW 4-C';%=+X(U6_UGPK9WVI1>7<N/FR,;AV./>MZ6*.4;98T=?1U!%/5
M0H 50 .@ JV]+6,TK2O<=3,Y;%/JAJ\M_#IDSZ7;I/>8_=H[;1GUS4=2F>)_
M#:&&;XHZF)41]LDQ4,,\[C7KFJ^&;+5;W3KL*L,]C<+,KHH!;'53[5Y?H'@'
MQQH?B ZY#'8-,[,[QM-C=N.2.E>QZ=)=3V$4E_ D%TP_>1(^X*?8UK4>NAC3
MCI9HY7Q]?^%].AM;K7[475PC9M8ADL6K@_BAJ>J:MX/L+J]TI;&U>Y!BW.#)
M]TXR.U=)\4/!FL:_>:?J&DHDK6W#1L<$<Y!'K57Q)X2\9>,/#B)J,EI!-;D-
M%:1='.,9+=C[41:LG<4T[O0[GP@#_P (EI@<9S;KG/TKR#QYI;>#?%RZOX>N
M"CM^\EBCY\DGU]C7HNDVWC2Q\(K;^38?;T010HSX"J!]XGN?:JOA_P +ZU:^
M&]8M]6L;*YU*]#$RF;<)2>Q.. *:DDVQ.+E%(T?AU<:7?Z +^RD:6[G;==R2
MG+^9W!]O2NPSBO&_"7@CQWX1U-KFT%@\$G$L!G.UA^745[&NXH-PPV.1[U%1
M)2T=T:4F^7568[(%<IXQU"XF6#P_IN3>ZA\KL/\ EE%_$QKII?,$4C1(&D"G
M:I. 3V%>2P:%\2[;7;W4X#8">Z."99-P51T ]*(*]V.<K6/4-,T^TT/2H+*
M+%;P(%';/J?QJ[G'3I7G6FZ#XWU76[=O%%W;C3;<^88K9^)''3/M7<ZG-?V]
MF6TZSCNI\@"-Y?+&/K2:MH"=UM8\Z^'./^$^\4_]=3_.O4LX/2O+?#GAOQGX
M?\2:AJQLM/G6^8EX1<[<<YX.*](GDO/[-D>&%#>>7E8V;Y=^.F?K3F[L4-%9
MG,^+[B76+J'PM8[O,N</>2KTAA[Y]STKI[6VM=,LX+2$+%#$H2->E>4Z=H7Q
M.L;Z\NH6T_S[Q]\KRON^@!]*WM!T+Q??>(8KWQ7<PFVLSO@AMV^5G]3]*IQ5
MMR5)WV/0NU!H&:6L3H,S7M531-#O-1< ^1&6 /<]A7-?"^V<^%VU.?+76HS-
M<2.>I!/ _"IOBA:W=WX&NX;*)Y92RG:@R2,\U=\"1RQ>"M,BFMWMY$B"M&XP
M<UK9<ES&[Y[">.M1GTKP;J%S:N4FV;5<?PY.":DT#0=,@\,6MLEM%+%+$&D9
MU#&1B.23WS6IJNF6^L:5<Z==+N@N$*,*XS2X_&/A2+^S!8Q:S81_+;3";9(J
M]@W':ICJM-PDDGKL<_<Z"G@SXHZ3)I&Z.TU#(> '@'O^'>O7CUXZ5R.F>']1
MU'7X_$/B%8X[B!"EK:1-N6('N3W-:VL7FN6<T;Z;IT-[;E<.C2['4^HXYIR=
MVD@BK)WV+>JQPS:5=QW"J8C"VX,,CI7GWP7@=-&U)\$6[W)$?OBM/4;?Q=XL
MC.GR6L>BZ:_$\GF[Y77T'IFNMTC2+31-+@T^RB$<$2X [D]R?>B]HV"UY7Z&
M@*YWQMI&IZYX=ET_2[A()92 [-W7N*Z+M0:BYK:ZL>3+X<^(>G:0;:'6[5+2
M&(J(UC'"@=*P_AGHWB#4&CF@U,0Z7!=EIH!P7;O7M6I _P!EW0 S^Z;^5<'\
M'H)8O#EV9(I(PURY7>,9&:V4KQ;.=QM)(]%.>W%4=8BMYM$O4NPI@,#[]PX
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M^YY9G,D\S_>D8]S6M24:AH XI3111?4+:"4M%%%A@:***.H"44M%.P!1110
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MXP\":=X:LRKZG.A64L,A$3H3[G K6,4TF<TY23:N=YX=\67OB'P]<:K;Z45
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MZC)NNKZSEN6!_@!' _+%=7+J4/CS4M,L+63=8Q(MW?!>F[^%#^-59QM^/=B
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M7(=EYP?>B+5K26@IQ;=T]2E:WOA_QC!#);7,5U]GD$R!6PR,.AQUK-^*9/\
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MG Q5S225B(-N_,2FO&/B3IMU-XIFU73Y-MQID$<^!U(R<FO9FZ5QME;PW_Q
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MUWM&]HEVKU' %<E\*X_$T6B2S:2;2:T>4AHKAL%&QU!KLOB@[MX6-HK!5N9
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H@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>lixt-20250708.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaGHibP9z5Z8uekhvWB3bak6bykmYCYGoShkHW42gV0K -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:LIXT="http://lixte.com/20250708" elementFormDefault="qualified" targetNamespace="http://lixte.com/20250708">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://lixte.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20250708_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20250708_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lixt-20250708_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="LIXT_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" name="WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>lixt-20250708_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250708.xsd#Cover" roleURI="http://lixte.com/role/Cover" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250708.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250708.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>lixt-20250708_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250708.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockParValue0.0001PerShareMember" xlink:to="LIXT_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20250708.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:to="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Warrants to Purchase Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>lixt-20250708_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="lixt-20250708.xsd#Cover" roleURI="http://lixte.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250708.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20250708.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  08,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001335105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2903526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">680
East Colorado Boulevard<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">830-7092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIXT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember', window );">Warrants to Purchase Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants
    to Purchase Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIXTW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>lixt-20250708.xsd</File>
    <File>lixt-20250708_def.xml</File>
    <File>lixt-20250708_lab.xml</File>
    <File>lixt-20250708_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "LIXT",
   "nsuri": "http://lixte.com/20250708",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "lixt-20250708.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "lixt-20250708_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lixt-20250708_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lixt-20250708_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 26
   },
   "report": {
    "R1": {
     "role": "http://lixte.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-07-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-07-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "auth_ref": []
    },
    "LIXT_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250708",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://lixte.com/20250708",
     "localname": "WarrantsToPurchaseCommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Common Stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001641172-25-018256-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-018256-xbrl.zip
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M5W37Z:*Y<3U3M<KH0/8AQC;7(F97B]>7>]R)PPC<@8V(B!KJK%ICP,@L36_
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MC:-9=C^$U*(4_4/EY4+5E]%?86L\MQ&?=T=G1\P$)CHH<<&=?'OZ-'H!@^I
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MOC:'Z%@Z2>IHC=+F:*HX<US#E7JR@E_1 <E':,[^W*NDSJNNH3(/C5<T4A>
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M;G27G5,N_VM$EB4GII)^:PFNX5U-Z,5B^'\C93@%FRMA38?B)<#IL7;A]/F
MJ-9W\#K.9Y80G"ZM0$&QW !X46-WD$(_G)I-5S==PEI:XH$-;:E GR&G'S &
MK<&J)E*0GJ-M5)/>R7%&=>#P3DMG%77MP212GIJ#R1PC)3Y?06!-E_2># MW
MN*'\<KRYB!#K'"?1&3M',?\VU/BO1ZMP4Y&+ZT1PP=;MXSJ$R!KA!T#8R:E,
M7VOR1L0QNMGKL,'%K27-2SH/F_??281^1S%OQ^V:J:4FT=0UO ^2PX.3PQAC
M!0>G\M_'F#:+__A:/OA&_ONM_/<$GZQJ_O?CP]$ZX$+-?&@=P4@TQNB67(PA
M!L4NNJT:Z"EQ5%)73YX\.>.^CE<=#S=XWV/'19W$,Q(L:\ M(!/T[" [1+H7
MMI3?27&' V<R%ZJHKJ74JHQRD6!PQ9G[G774\16$$.Z*R\02I T,D-B(\.QD
M#*TNC&&JMAB4DMNRV_>M*4%"9SCV!=WDG#F&)5_8,:1Y>,4Q((W^"*,ZPU'-
M9W"+R$JRA6,J3+A%DMU.].BHIS+Q>S0L/#0-4]CY)ZQ+@?HU103]/3>F)QDH
M=%)(!8ZVNE3TB7%5!)6JN'0[;5(G::2I-BMT2%K+>CY3ID=XLGF@:$N-H.-J
M3268W 67H5MPSJ*NN"6JP!H:%.]:G3<?S4FN:>[0.\ '[)H1ZNS2<:\"K=S!
M"Z5QN2^&VJ9AV@8'=17L*?4[X<-!I559K?.46N%HG4YTDD[U%-(2L]%:G0!"
M@'N\X6*W_62YQ,RBQ.3S1$75#';RP<GY ]Z^AK_L)W:<@<;CY/?N,F\(Y(=J
M_+":[^Q-IW)6WQ)*-.Q4PLHZ3X8O+M#ET9-04+$NHM(<R7[RK1G/HE@4>;.2
M7 ;$YZOK9I-L\.Q9)Y?)OW,^=[2[&?UW"?%XU%62I50EZPHUP5852E]B8#TE
M65XY19R%FH5@LVNT"$8I.?K>9).G)1Y0/\/:?NY-S;3+]F18N,N>V7I]&!2A
M:-!KBQ\=W6;],D4Y)_&O$JDJN<&,3M@&',NJ04*A8^-1&S>/$@/"ZA/ESO"M
MTZ2P30@Q+>"20XLR/7\AC#^-N< X<8AN!>$G'NA1 E>01R9/FUY&H0M&V%"1
MQK;36"@7$OYLKJER.FC"<;_VJ(\]"L W'&T1-SM#X<U/7.Q1BZR)_H4X>B5+
M%IT%,=G?/1>KAA:9L/$N1GBAD34A^9-51DPO8P2L$XLNY6J8%"Z;VQ5[&5\.
M5YF@ER5/J^F0LC27P)=BX'/.?XCV(6%8?7T_=V(7-"_!BE8+1$E+O:R,NQO
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MP%;XF0L8<3A-DB8T]SW#SAL\B5CKM?5_/"Q+*HQ\&G0A"%\GWB!<?$Y31#S
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M,I#!(=\Q1E^FX-WX>/UZ595 *#FPGU3%)P46!,,,%F)JM0_Q$Z@72AX$5T^
MT4RLS#IH662LP<XY%VZV:HLU6AUHU@-00\.>H!OAE1E*_']K/IX(V1<!6P%V
MG*ZO 0Z51=O=D]DD!C8T2&1B" H[*ZDH1=2MPJ_74D=J/H'D*4 &!X1*K*H7
MO"6O[1K85)J=V',QM 5]CSJH_(1(EWPD<7*556C(6TZ8ID^9KDRGMA7G_@GJ
M_I%FJCI0>"M X?_ APRRZA%"\$CF+ ZBS2%1,.5*7XQ/4'!R-L\0:^[%,BA]
M9[P8V =F2T\Q'#E87[LL<W3DVX)=0_"9!IP" ;4^QGDUEF='^8U:H)#8W&V#
M-5;>NT3IJ7!B3EKS3WPG'6FR3>SIE@.A _K+9YG%N@T20@I2_(%[E%K)Z$@>
MA1[66H8F]).K4<Z5"-919"IH=&XG><'19(Q+(I)X:OI?$.@/N TQ#F$.RSQC
MDP!W/49VK%3!]-K]A6414HY,A %;RP.AEP/$#:/KP9REO )(,*S)YRT]B@[T
MT31UE0\272["TR[/G*K#=7)5MF8YX7UA+S:W#C T=+\5(,%T1>M(P4#J*ZEM
MX>1"-Z@8QS:]LU837JJ@TZ#6:G\@KD"GMA63_W%6CP@O3-L>:-+&57IE[KAC
M"(GI*@)?=,^*=P84%KZ8YX;FG+'<:V1WF-:GE1_XVD114!^=NR .!L85G.8!
M%-@1FJ44U!LP.RIQ4<PPU&0.4<+\4UPLC;Z#!D1'T<:E!+US$K,F-@N.<=&.
MUT$XQ;\JS&<-'[^"^*!X7H@:8>&6D5D -D, LX)Q/WA;74XSS 68,Q7:C-*7
M6#8'LP'_1W!/G(G'DW\$P<5+.-+H,WJ,9-P2T%PVAM<TXT0& M%D4HWOABF0
MC"+!M4#AM3XSP6CNR,,3*9ZHU"JE2A(/E2YE'G13*DK=J%JIJT,S@]=6'(&/
M,WD&^BV$?:>)@?AO0/F!240JJM)*POR:#F63+//T_!PRG(W"VL\K+$A+\W$P
M:2Y;X0I>R/2'PUY4T!=K.MHX=SHBB+M^EBX/6_!]X0#4W"NB!$-S ^Z\!8RP
M&R^9B1%VDE(/&%'F\30-SWB5],1(J]"I;47:?NSF&U> "[;X#.Z0 53+P#)\
M4FF$6Q0!E8VQJV;&!9R253DMZP83V-.LH,)M\XCRF@]2V27K:VRSHN(39,92
MM#C)[H9?XN64_3%"43K..IU1)@K/TY)**_ 4'<'BGC)IM63?-H)#BML(W)T#
M/B:G>=;R>14\'A\R@3JQU+CJ5XO'99"<M0V1MV%3I.(6T(Z2P5/TY+5I0#U)
M(>$?BOUB0W"_F2&D--*DL2/8LAU[ZL[/@M)\MS20;U!*R^:5N3G!0("\H"K?
MFDN2S9KW6'!5C9^0ET])'Y7)'IDU;-9A!0DI<Q\5QEO;A#1S.<KQDG69("5^
MQH>).WSZJ-]*=>H^B9X7?:)GF8F>%WVBI]^^GVX2**[_63;./4*6/0=8H'L8
MSGD(@C13#G7;\E2(2Q'NWN-;09KKY!P)LS%(,R6'2"X-H+&0./4XG0$#Q,#3
MWG#XX*YKAS2?9YG7HJCZV"VRE'2%VJ()B ]R;*4LL@9N-&X:^'@ F\"*G71L
MMAS<K1@P+.I4&2'7>&%[G(QTCPHDBOE&S;^T[^EYX8MQG.@^<-R*6\OEU8EH
M6"Y">*$GLD"@S3I+6H$3$W.$FB0@)@2SLC$"C<Q<&A\38UYJ//I[>P4ZM:TT
M"H[2:_(#3K(FV8'TF2HEZ)*OZ!TX2W_'H,V<'H$L0_1C;4MMK.<<BEQ$"5H@
M.JGI"SA.B:!6%R9293Z-16P.V&;'S%RW/:+O04@BIT+HH2W=2S"&(P QZT&D
M5:;( 1!!J\+G0=1X4J4M4)-Q0XSWD$&8 5EF(+:?PE@/Y P$IM.J!$'9O#XO
MD?[L[)I:4?DA$(R(3) L [Z-$0?AR<)R NN==X)'B7$!ZB:CMV9$9E!UBA0D
MQ%;@>:WC!I2B"V5[\41+B]^K=MZ,^(PG!"_(>3.D&'\[HD -(LC-6)L^-1CT
M(5\/!GC$[AB&V!IO^:DS:GU-ATY\(%W"C,UVTB0#B--%%20\C.1[ ?A2Q9HN
M<Q&I$4F:L9]L42E))*62G*2LNHMT;'FQS189<TZCN];,(B@G$_OY<D3717^"
MKD"GS EJJSKWS"OF&;YG?>V <M!FW3G;18"3A^JRAT6$X?J@<BM A ;<$6YG
M1H]//)\P7SJUH-ODMS(O&N=_1U@Y DJ- =L1\5AL/0>0!>Q:A<>U\DG:IJB(
M3,O]RA8RW]Z&6WIZ WRXK'P(<.SK QD=/G 84!+2]KL[RU5N-,+C&8$I*V1T
M4-R6UEP$PCK; TR(<G2$$I4I3Q2(Y@DOC>W$[Y!.14VJ!NN (#XFT Q 8K6S
M.1^%?$7K=U?>5*4C*:"@^ADJZ(7VG5<E:.Y&*3R]&:LZ]3.=;.P-UO;07])V
M'+4=G[LM-:4ZNT92VX+ 5D; +;+R&&IG3IDJ)\[P-E:6#[=HVRQ,9:F:"]HB
M>>-7\3NIP8E_K=K.TKT#$XT5A[@*G,22!73C*G0H;IM 8'4RJ75PSP4M!KQO
M+#"/I@&%,:\*<R@@W#KC*BHFG9?4%%QZYN3#+>$(XF\$M6\!\1Q<P^#6T"8>
MS_(BKYN*,OQ=?H0(#4Y0!B7-PA3Z"&!#!6TKX1/T*?)(D.T"BZTHH>+W3AC5
M_5I8.F;]3XJW&53-VN2A'55=C:.W&.S. E:J_62]^-U:%0\3=K3FV7-&9UKS
MJGF@*)+0AO?%G4,^B+&>S8U_5\B25BS977F#:IZ:196E-JEAXQ+T6T4<(^R\
M("F<CH*#N=$QBTXJ%\H3<LZ6S08N;Z<4)2\TGBYZY^6+Y4Z4)V$.6$C 3J\'
MJON+15+4^$.,4,0\.]_%MQB3]CP<E*69.ZP !<'04 ,*?M<-+O:FVQ*#UMM]
MT'J90>OMKR5HW>_:!W"X+!'&?FYN*@RZ&).,8K.^$[4K^MD1@:W&)3<QY@NQ
M"?L\&^JUQ.,I4XP25_,MH>3U-2A9U923792TOFJ<]6C%PQ*0+I^B$= 6&-NY
MH96N"$^:":834)AG!4%1B@ "!BV ;+/S%%1B&&,2F("]]L)UA+RW9:9W'#)S
M^1O/8]Q2P,2,.89Z6,G2@NHI4]]'/5:B4V836EZ+$PATC--KH"PX,?L"?DK>
MP0V'/V7-:$LV)6!)T#P'.F#PC.9S<'7-VO&HV26(8)QQI>N4VBI0B@7.<X>8
M<F7 8KQBQ%023AYN6O(VR>O6N(!0*8R<[0[+QR\2-3^,"(CC12]Q52L8([;<
MQ,B+C\0RY*_)&^!TZFD\5Z%3VUO/;<G;KN)>"<K>(DE"E:V<P4'W#2U4GW3(
M<VS)V^88,P1_H4IE#ER[;9$3[R]\A/6 %]PS:4'P*<0D<;U! 6&V:5*UTXQI
M5IPBFH321161:?33V5E^WC+];)79](*Q5#$*S@0FF >LTDGC"L59+(-W%;./
MV,SE?7AI.%1B.7>M5H[Q+%UXA.,'& '"E#'G4Q#$BN"QBC&85@<YA@[-K6Q#
MUY.TD2@-(1W#^L,_3] O1NI@HB8IJRO@N*D)=CJ?YBA/0_\<YXCU&@MU"P0Q
MSEBA4M_; JGV@FG.4G -QRG#%(%2W;"R$;XHWR/;G(_UQ+$%DQ]V]OX^/%Y?
M.WR;_-?[XU^3T^.]G7VS^@^2G8-?DYW=T[W# _.D]WNG@^3P.#DZ/MP=#L%O
ME(^8;^V=O-G##R:OCP_?__+N-'G]*_[M:.?XU/STR\[>P<DI_N;P]-WPF'YO
MFOENB#_N#4^2X<[NN_6U_SXX_&">O0]??V/><#H\@.?N[._#QP_Q&[\<#W=.
MA^9YPW_ GY.CX?'?]DY/AV_PK4='^WN[Z./N[WPP1L'P> B_?GURN/_^= B/
M>7^P>WCP9L\]=^_X>/CW0_@2OG9];?B/H^/AR8GY)X[.2?+VT'S"M!L'!UX#
M0V5&D$_H/N!R^U)_Z-;_M/?S/_?W_G$*6 (+!I:@F(KLG=A2S2/T'-ZB%D[]
MKY^^V7LP+>G/T'>9O$XG;@DR?=<'F9899/KN:PDRW6F%N]:LVG:ZTU'R[\9[
MK"]^M%$5_VA9Z1/E<]X%"TP>L(V6V:6]@_6U#WNG!^9B3SZ 67#X=A"K.*8$
M("2G'/_I#8N O)9Q.[UVA;>4@_;=L+1M+LJ*5-.(+J!$_<#4FMQH4$_RJ@;D
M))($@A=T5EX^'*[Q3YF(^-IR5X:^(L(KY-[=]FZ0A3?-7_"@5/?)W5\0N7G^
M(L>NN6UV#Z$_!__QE^<?T?C(!;:\0^[USW#&#:FIK_<.3X>[[PX.]P]_^35Y
M=[@/(WYB3..#W2W/PC67F.O<E]8A65FKTEZ08A.V1&@C>/D'6!KZ0\>U$.OA
MH1;JQ^ZL[;\^[# %I\6GS2>W^<4J-OKY"K;YQ<L';O1W+Y]2*X<0WM\MIV65
MCLOD==E"F7HU-M]L<W.M/GOY=/#3ZV/NTE%:I^9R2P?)[D[RZMFSI\_<WW8:
MYMKX(?DE0_YIN/7K\ZFYA]VG=B_R;)(PV92YW0^)+/G+W:USB&46Y]9G>Q;&
M$Y8],Z^O?[AQ+=WL0](#/_:0IJ7\./X;'[WH='X9]]I2SY'/OFR'P&'V [7X
M?&LN._\_GY_/$:*Z-2IG7^XN?\B1P5C'"MA5?&KS26^/[B^_X4O=.)^WH5_/
M+C@%F/@J; .T4-@VNLE,^4*;_R@V P=Z5SWN=TL*X?L^A;#,%,+W?0KAZTLA
M[*%$05GU.80O.G2],(= 92?$T0RE-9^</X#J))<R2"1C<$WY JHX^AP)@R\0
MD?!(,P4?'8!]^L Q-KBAJ)FZL/A>T9VSCX_N?*Y>_O/?_^W5=]^_^O%?7Z=?
M\RCL[<<^2=8XL-MQQUT1)_:*N/LV#1O;L<L_>N/V4][ORZ]FDKP;,K8E/]=E
MV5^0_4;\FC<B1F?[G?BX)[G?B2LP29A'940%09SZ'?EH)[O?D2LP20N0AA"
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M<O"B@^;"1'_*TW^UY1,^W;U#^:>*_GH8P8.:,BK;)L\*>'9;J>? &^LV@7_
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M@ G"GV ]:&+XY"T^J#+_:C-8:5J[9(LOI\_">EU$ZK-'T0N[DLD'TM++'%1
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M+/.*EP.C35G!H8B4W1^P4Y>PO;!IU58[12J0-'E5.AFX*&T-&-@@2WC7P/Z
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M#HJ CG+H-'D_9.EO.FO^?'=T_,>^9[(_@/L#>.]K_FA'#N!;<PZN*&?B)^9
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M1(/S[UUM1SQ"P**N!L_%(H^=SX:>ZY^YURD[,"F6*K(M1BF#F$K\#C*6V@K
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MZ8S2^6*R!.M<JDLY8^J/\YFT7BBQ"U5KQ''$S])'/QBSL5%US$HT-.F&-<<
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MRRI L_I:94T7P":I,<B.63@L!B)BG)\/@\%V:XP7J*I6.:]1-LP'.R@#VB=
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MS=W"I)PBO+433,>#(4&P:QK>8\_([2'MPWF;.&\>#EDI%!OZ%M(7C<Y^=<Y
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ME\=_/.R&RP+*+Q<ZHYQ,GC"_T679.$*PS!87-E?PQ.V#\/FG_ )0,NH-38E
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M[_ELL>6_WFYG%"<ZQC0WE8%%R3B,D9J5<543_%#A9;<T[:@"0D)V=[Y@@_B
M#;QT(X\-&-0CU 62BLM<3^X1$7,']:@/WR! _$5YA644H-06K*!!HC-I@$A/
MI:,KN,":<7$Y%C"E&'?&?Z:&<<DL^!0*@.>T.95MH*+$[3RO2K@D"G,.5QIG
M3BL:Q*K-HW568]/KEN(>R%@SOC%N2VE4^XYY.S I,"Q..X;%BJ'Y8YA3WZ!
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MK$S#4!Q\$:.2JGGQ0/@N2K,55; V?%Q)#2"?9,9 ZE(B<,$S@QF-#'X^HW/
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MVK9HC7'[\QVF19U6U[Q''XY_?7UR>OSA^*C?>__A^,'+W]\>'1]%?QQ\^'
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M*8KQAJWDP0'(:FU;H<.QL Q&07(0$5 UIG:X9L+\?I#DY*/H;Y,5CC,Z2LD
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M7+)C!8_#$<#;73J0KU Y>2MB?9O6>FLTQ;OFD/+^SFVGII?\!*QEDEV2D?W
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M&(V)1I#2].1$#5-[1I:V]PG9K4&C0[PU4-DXO1V""Q.F[!RX$1RMY?::.M<
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M0,E*@X=">);3"<IPWAM$)#%3HY5&10S4!@V=0JI7MOW:!,4870QBC)M LBC
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MS4OH#R_>'?V3RD1?G?[VYI?_#U!+ P04    " "EB^A:,\.-0V\+   E1
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M:WUWC?[,A_N['_3G0?X'4$L#!!0    ( *6+Z%K+P\V(@PP  &8U   *
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M\S+XD^T(J=5+L96NPK:ZEWN5"710"'L&%8?N]0BA!C%&3,1HFT1D&$#3(.*
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M60KZ'O]$SF2PG#].:F5+OCB_4C.OEW/_.7(FPX6V)9N," >)#Y6=>SH6ZO1
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M9 ^=-CR,G4P<.JL._DDX_!0A/&C'E^T<++[EM1N""GFXF6O)B_5[C]U&"?=
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MH!MU0\BH%)<M#'D C0Z22PP7,XA)#'U@V2Y364\V774,"I=3 /T''T/++<7
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M[\\WI$[O*H:\J&W6"VF537GU 8N@MEK<>BM?LA0_)9=DR! ;]D6=*,X.JFP
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M68?"$ 5$A=T9@$4N1DJ-A-P+&#<\7F/^.(VCCJ&B*72+!F2TSH:I"@@.P!I
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MD>-FKUZ=*,QO%9L2M>BSL'H\*=I"J>/FK'ZE*-@'9-Z+C-MLQ):+PJKI.XM
M@X";L()TH\2B)T*I9G+MKG57)N8,771EY!WV*PI"XX*;R>[  "4ZYU%DN.GL
M/ZNDXXM)J3GX*58-(N'16Q/^A[OQ/X3SQ\UP*_76A/_1;OR/X/QQL]Q*O9C\
MN^;CC1K(1\?C<Z<QE#UNEENA%9-\ZO^-NE7R@2U7U%?A+Y2 QJ .R:]?->HI
ML)P10/I_;@D%7X=$N%PE)O!;J6/"_V:SJHEHN3T4?AU28I_B?=_>7'8 >U_$
MM59JRP0*&C<++M6U;[8VU(H2=X?>M("2Q4UMRU3M&>RUM ]E)E)X;PL7K:"
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M>#$P+3$N:'1M4$L! A0#%     @ I8OH6KW:Y-Y*A   K"X#  H
M     ( !U*$  &5X,3 M,BYH=&U02P$"% ,4    " "EB^A:6R7/07A1  !&
M- ( "0              @ %&)@$ 97@T+3$N:'1M4$L! A0#%     @ I8OH
M6C/#C4-O"P  )40   D              ( !Y7<! &5X-2TQ+FAT;5!+ 0(4
M Q0    ( *6+Z%K+P\V(@PP  &8U   *              "  7N# 0!E>#DY
M+3$N:'1M4$L! A0#%     @ I8OH6B=$<I$,&@  FL<   L
M ( !)I ! &9O<FTX+6LN:'1M4$L! A0#%     @ I8OH6EK9F>K# P  YPX
M !$              ( !6ZH! &QI>'0M,C R-3 W,#@N>'-D4$L! A0#%
M  @ I8OH6FTLDOOU"   JF@  !4              ( !3:X! &QI>'0M,C R
M-3 W,#A?9&5F+GAM;%!+ 0(4 Q0    ( *6+Z%HW"6+FZ L  &R0   5
M          "  76W 0!L:7AT+3(P,C4P-S X7VQA8BYX;6Q02P$"% ,4
M" "EB^A:;O]Y5T (  !$8P  %0              @ &0PP$ ;&EX="TR,#(U
B,#<P.%]P<F4N>&UL4$L%!@     *  H 5P(   /, 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:LIXT="http://lixte.com/20250708"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lixt-20250708.xsd" xlink:type="simple"/>
    <context id="AsOf2025-07-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2025-07-08</startDate>
            <endDate>2025-07-08</endDate>
        </period>
    </context>
    <context id="From2025-07-082025-07-08_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-08</startDate>
            <endDate>2025-07-08</endDate>
        </period>
    </context>
    <context id="From2025-07-082025-07-08_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-08</startDate>
            <endDate>2025-07-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-07-08" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-07-08" id="Fact000004">0001335105</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-07-08" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-07-08" id="Fact000010">2025-07-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-07-08" id="Fact000011">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-07-08" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-07-08" id="Fact000013">001-39717</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-07-08" id="Fact000014">20-2903526</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-07-08" id="Fact000015">680 East Colorado Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-07-08" id="Fact000016">Suite 180</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-07-08" id="Fact000017">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-07-08" id="Fact000018">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-07-08" id="Fact000019">91101</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-07-08" id="Fact000020">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-07-08" id="Fact000021">830-7092</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-07-08" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-07-08" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-07-08" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-07-08" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From2025-07-082025-07-08_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000026">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-07-082025-07-08_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000027">LIXT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-07-082025-07-08_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2025-07-082025-07-08_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember"
      id="Fact000029">Warrants     to Purchase Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-07-082025-07-08_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember"
      id="Fact000030">LIXTW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-07-082025-07-08_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember"
      id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-07-08" id="Fact000032">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
